Citation Report
List of articles citing

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

#	Paper	IF	Citations
2244	Therapeutic applications of anti-sense mechanisms for the treatment of cancer. 893-902		
2243	.		
2242	Common corruption of the mTOR signaling network in human tumors. **2008**, 27 Suppl 2, S43-51		237
2241	Stop acting so immature. **2008**, 8, 905-905		
2240	Pathways to cancer therapy. **2008**, 7, 875-6		29
2239	Cancer stem cells in brain tumor biology. **2008**, 73, 411-20		61
2238	The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. **2009**, 119, 747-54		165
2237	Divide and conquer: progress in the molecular stratification of cancer. **2009**, 50, 464-73		4
2236	[Médecine/Sciences as time goes by]. **2009**, 25, 3-4		0
2235	Simplified DGS procedure for large-scale genome structural study. **2009**, 47, 969-71		2
2234	A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors. **2009**, 4, e6274		17
2233	Glioblastoma formation from cell population depleted of Prominin1-expressing cells. **2009**, 4, e6869		47
2232	Genetic epidemiology of glioblastoma multiforme: confirmatory and new findings from analyses of human leukocyte antigen alleles and motifs. **2009**, 4, e7157		24
2231	In Silico Enhanced Restriction Enzyme Based Methylation Analysis of the Human Glioblastoma Genome Using Agilent 244K CpG Island Microarrays. **2009**, 3, 57		2
2230	Investigating Gene and MicroRNA Expression in Glioblastoma. **2009**,		
2229	The ABCG2 resistance network of glioblastoma. **2009**, 8, 2937-2945		86
2228	Emergence of single-molecule sequencing and potential for molecular diagnostic applications. **2009**, 9, 659-66		25

| 2209 | Molecular classification of solid tumours: towards pathway-driven therapeutics. **2009**, 100, 1517-22 | 59 |

| 2208 | Targeted cancer therapeutics. **2009**, 69, 1263-7; discussion 1267 | 122 |

| 2207 | Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. **2009**, 69, 6889-98 | 120 |

| 2206 | Signaling in malignant astrocytomas: role of neural stem cells and its therapeutic implications. **2009**, 15, 7124-9 | 28 |

| 2205 | Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biologic evolution of prostate cancer. **2009**, 27, 3088-90 | 6 |

| 2204 | Striking the balance between PTEN and PDK1: it all depends on the cell context. **2009**, 23, 1699-704 | 16 |

| 2203 | Relative expression analysis for identifying perturbed pathways. **2009**, 2009, 5456-9 | 4 |

| 2202 | Integrated study of copy number states and genotype calls using high-density SNP arrays. **2009**, 37, 5365-77 | 93 |

| 2201 | The role of autophagy in sensitizing malignant glioma cells to radiation therapy. **2009**, 41, 341-51 | 100 |

| 2200 | PTEN, stem cells, and cancer stem cells. **2009**, 284, 11755-9 | 107 |

| 2199 | The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. **2009**, 106, 9435-40 | 196 |

| 2198 | High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. **2009**, 114, 647-50 | 348 |

| 2197 | Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. **2009**, 106, 18351-6 | 226 |

| 2196 | One step forward toward identification of the genetic signature of glioblastomas. **2009**, 302, 325-6 | 2 |

| 2195 | PCR-free method detects high frequency of genomic instability in prostate cancer. **2009**, 37, 7441-6 | 7 |

| 2194 | EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. **2009**, 69, 4252-9 | 201 |

| 2193 | Oncomodulatory Role of the Human Cytomegalovirus in Glioblastoma. **2009**, 415-440 | |

| 2192 | Ultrasome: efficient aberration caller for copy number studies of ultra-high resolution. **2009**, 25, 1078-9 | 17 |

| 2173 | Oncogenic EGFR signaling networks in glioma. **2009**, 2, re6 | 239 |

| 2172 | p53 Pathway Alterations in Brain Tumors. **2009**, 283-314 | 2 |

| 2171 | Using mice to examine p53 functions in cancer, aging, and longevity. **2009**, 1, a001081 | 41 |

| 2170 | Emerging roles of the EBF family of transcription factors in tumor suppression. **2009**, 7, 1893-901 | 63 |

| 2169 | Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. **2009**, 11, 803-18 | 32 |

| 2168 | A single-sample method for normalizing and combining full-resolution copy numbers from multiple platforms, labs and analysis methods. **2009**, 25, 861-7 | 32 |

| 2167 | Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. **2009**, 11, 477-87 | 99 |

| 2166 | Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. **2009**, 69, 9065-72 | 437 |

| 2165 | Molecular neuropathology of gliomas. **2009**, 10, 184-212 | 33 |

| 2164 | Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. **2009**, 4, e7752 | 390 |

| 2163 | Epigenetic deregulation of DNA repair and its potential for therapy. **2009**, 15, 5026-31 | 49 |

| 2162 | Sox11 prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation. **2009**, 69, 7953-9 | 82 |

| 2161 | EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. **2009**, 8, 1751-60 | 55 |

| 2160 | The function, proteolytic processing, and histopathology of Met in cancer. **2009**, 103, 1-23 | 20 |

| 2159 | MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. **2009**, 69, 7803-10 | 56 |

| 2158 | Bioinformatics construction of the human cell surfaceome. **2009**, 106, 16752-7 | 91 |

| 2157 | Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. **2009**, 69, 2091-9 | 174 |

| 2156 | Identification of rare cancer driver mutations by network reconstruction. **2009**, 19, 1570-8 | 80 |

(2009-2009)

| 2137 | Glioma stem cells: not all created equal. **2009**, 15, 247-9 | 19 |

| 2136 | Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. **2009**, 15, 514-26 | 199 |

| 2135 | EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. **2009**, 16, 9-20 | 340 |

| 2134 | Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. **2009**, 16, 44-54 | 113 |

| 2133 | Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. **2009**, 16, 463-74 | 241 |

| 2132 | PI3K regulatory subunits lose control in cancer. **2009**, 16, 449-50 | 25 |

| 2131 | Should individual PI3 kinase isoforms be targeted in cancer?. **2009**, 21, 199-208 | 99 |

| 2130 | Translating biology into clinic: the case of glioblastoma. **2009**, 21, 311-6 | 18 |

| 2129 | Book review. **2009**, 13, 294-295 | 1 |

| 2128 | Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. **2009**, 8, 1056-72 | 473 |

| 2127 | Molecularly targeted therapies for glioma. **2009**, 66, 717-29 | 20 |

| 2126 | PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain. **2009**, 57, 1835-47 | 63 |

| 2125 | MAPK pathway activation and the origins of pediatric low-grade astrocytomas. **2010**, 222, 509-14 | 73 |

| 2124 | Genomic aberrations in 80 cases of primary glioblastoma multiforme: Pathogenetic heterogeneity and putative cytogenetic pathways. **2009**, 48, 908-24 | 36 |

| 2123 | Analytical methods for inferring functional effects of single base pair substitutions in human cancers. **2009**, 126, 481-98 | 17 |

| 2122 | Glioblastomes: aspects moléculaires et prise en charge actuelle. **2009**, 11, 67-71 | 1 |

| 2121 | The future of neuro-oncology. **2009**, 151, 1343-8 | 3 |

| 2120 | Oncogenic role of microRNAs in brain tumors. **2009**, 117, 599-611 | 106 |

2119	Targeted therapy for malignant glioma patients: lessons learned and the road ahead. **2009**, 6, 500-12		71
2118	The evolution and application of techniques in molecular biology to human brain tumors: a 25 year perspective. **2009**, 92, 261-73		7
2117	Emerging functions of microRNAs in glioblastoma. **2009**, 92, 297-306		93
2116	Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. **2009**, 95, 151-163		38
2115	Brain tumor stem cells. **2009**, 34, 2055-66		17
2114	Glioblastoma multiforme. **2009**, 11, 297-305		2
2113	Neurofibromatosis type 1 and associated malignancies. **2009**, 9, 247-53		36
2112	Genexpressionsprofile in der onkologischen Diagnostik. **2009**, 2, 44-52		
2111	Systems biology of breast cancer. **2009**, 1, 238-245		2
2110	Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. **2009**, 64, 863-6		7
2109	Genomic instability and the selection of treatments for cancer. **2010**, 220, 281-9		46
2108	Non-pineal supratentorial primitive neuro-ectodermal tumors (sPNET) in teenagers and young adults: Time to reconsider cisplatin based chemotherapy after cranio-spinal irradiation?. **2009**, 52, 796-803		16
2107	The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma. **2009**, 2, 20		18
2106	Decreased expression of germinal center-associated nuclear protein is involved in chromosomal instability in malignant gliomas. **2009**, 100, 2069-76		12
2105	Genetic alterations and signaling pathways in the evolution of gliomas. **2009**, 100, 2235-41		322
2104	From cancer genomes to cancer models: bridging the gaps. **2009**, 10, 359-66		29
2103	The cancer genome. *Nature*, **2009**, 458, 719-24	50.4	2272
2102	Complex landscapes of somatic rearrangement in human breast cancer genomes. *Nature*, **2009**, 462, 1005-10	50.4	684

2101   Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. **2009**, 27, 77-83   190

2100   Microdroplet-based PCR enrichment for large-scale targeted sequencing. **2009**, 27, 1025-31   373

2099   A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. **2009**, 41, 455-9   287

2098   Genome-wide association study identifies five susceptibility loci for glioma. **2009**, 41, 899-904   640

2097   Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. **2009**, 41, 905-8   396

2096   Perspectives on the development of imatinib and the future of cancer research. **2009**, 15, 1149-52   87

2095   High-resolution mapping of copy-number alterations with massively parallel sequencing. **2009**, 6, 99-103   417

2094   BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. **2009**, 6, 677-81   1062

2093   The UCSC Cancer Genomics Browser. **2009**, 6, 239-40   141

2092   Hybrid selection of discrete genomic intervals on custom-designed microarrays for massively parallel sequencing. **2009**, 4, 960-74   153

2091   Targeting PI3K signalling in cancer: opportunities, challenges and limitations. **2009**, 9, 550-62   1915

2090   Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. **2009**, 8, 806-23   667

2089   A network view of disease and compound screening. **2009**, 8, 286-95   219

2088   Targeting the phosphoinositide 3-kinase pathway in cancer. **2009**, 8, 627-44   1895

2087   An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. **2009**, 28, 2773-83   185

2086   The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. **2009**, 28, 3586-96   65

2085   Driving in the melanoma landscape. **2009**, 18, 506-8   8

2084   Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features. **2010**, 30, 392-400   35

| 2029 | William L Gerald, M. D., Ph.D., 1954-2008. **2009**, 11, 1-3 | 1 |

| 2028 | Cancer genome sequencing: a review. **2009**, 18, R163-8 | 154 |

| 2027 | Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. **2009**, 27, 4150-4 | 752 |

| 2026 | Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. **2009**, 27, 5743-50 | 464 |

| 2025 | Combining drugs and radiotherapy: from the bench to the bedside. **2009**, 22, 625-32 | 16 |

| 2024 | Current Opinion in Neurology. Current world literature. **2009**, 22, 681-92 | |

| 2023 | Treatment of recurrent high-grade gliomas. **2009**, 22, 657-64 | 22 |

| 2022 | Current world literature. **2009**, 21, 83-96 | |

| 2021 | Current world literature. **2009**, 21, 541-9 | |

| 2020 | Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches. **2009**, 22, 619-24 | 8 |

| 2019 | Sequence-based advances in the definition of cancer-associated gene mutations. **2009**, 21, 47-52 | 9 |

| 2018 | P-REX2a driving tumorigenesis by PTEN inhibition. **2009**, 2, pe68 | 6 |

| 2017 | Functions of p53 in metabolism and invasion. **2009**, 37, 511-7 | 26 |

| 2016 | Form and flexibility in phosphoinositide 3-kinases. **2009**, 37, 615-26 | 54 |

| 2015 | Enabling personalized medicine through an interoperable IT infrastructure: an overview of the cancer Biomedical Informatics Grid. **2009**, 6, 439-448 | 1 |

| 2014 | A Correction to the Review Titled: "Oncogenic EGFR Signaling Networks in Glioma" by P. H. Huang, A. M. Xu, F. M. White. **2009**, 2, er7-er7 | |

| 2013 | Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer. **2009**, 4, 787-91 | 25 |

| 2012 | Epidermal growth factor receptor inhibitors in oncology. **2010**, 22, 573-8 | 37 |

2011   Gliomas: Current Issues in Diagnosis and Treatment. **2010**, 6, 285-294

2010   Discovering tumor suppressor genes through genome-wide copy number analysis. **2010**, 11, 297-310   15

2009   A Bioinformatics Pipeline for Cancer Epigenetics. **2010**, 5, 153-163   2

2008   The genomics of lung adenocarcinoma: opportunities for targeted therapies. **2010**, 1, 1200-10   64

2007   The anti-cancer efficacy of curcumin scrutinized through core signaling pathways in glioblastoma. **2010**, 26, 217-24   28

2006   IDH1 and IDH2 mutations in gliomas and the associated induction of hypoxia-inducible factor and production of 2-hydroxyglutarate. **2010**, 66, N20-1   10

2005   Copy number variations and cancer susceptibility. **2010**, 22, 55-63   58

2004   Human variation databases. **2010**, 2010, baq015   17

2003   Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. **2010**, 116, 3268-77   903

2002   Pre-clinical transgenic mouse models of nervous system tumors. **2010**, 1,

2001   Akt and autophagy cooperate to promote survival of drug-resistant glioma. **2010**, 3, ra81   225

2000   Role of RAS in the regulation of PI 3-kinase. **2010**, 346, 143-69   83

1999   Chronotherapy and the molecular clock: Clinical implications in oncology. **2010**, 62, 979-1001   118

1998   Malignant gliomas: new translational therapies. **2010**, 77, 655-66   16

1997   MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. **2010**, 6, 39-51   538

1996   A scalable, fully automated process for construction of sequence-ready barcoded libraries for 454. **2010**, 11, R15   80

1995   [Neurological complications of neurooncological therapy]. **2010**, 81, 940-9   2

1994   Protein tyrosine phosphatases in glioma biology. **2010**, 119, 157-75   54

| 1993 | Molecular diagnostics of gliomas: state of the art. **2010**, 120, 567-84 | 208 |

| 1992 | The neural stem cell fate determinant TLX promotes tumorigenesis and genesis of cells resembling glioma stem cells. **2010**, 30, 403-8 | 41 |

| 1991 | Polymorphisms in promoter sequences of the p15 (INK4B) and PTEN genes of normal Japanese individuals. **2010**, 48, 970-86 | 3 |

| 1990 | Targeted therapies on the horizon for malignant glioma. **2010**, 5, 157-60 | |

| 1989 | Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives. **2010**, 5, 183-91 | 21 |

| 1988 | Molecular markers in gliomas: impact for the clinician. **2010**, 5, 201-10 | 16 |

| 1987 | Beryllium sulfate induces p21 CDKN1A expression and a senescence-like cell cycle arrest in susceptible cancer cell types. **2010**, 23, 1061-73 | 6 |

| 1986 | Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. **2010**, 29, 73-93 | 39 |

| 1985 | Maintenance of critical properties of brain tumor stem-like cells after cryopreservation. **2010**, 30, 775-86 | 10 |

| 1984 | Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. **2010**, 96, 321-9 | 46 |

| 1983 | American Association for Cancer Research Genetics and Biology of Brain Cancers 2009, December 13-15, 2009, San Diego, CA. **2010**, 99, 297-306 | 2 |

| 1982 | Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. **2010**, 9, 717-26 | 216 |

| 1981 | High-throughput SNP/CGH approaches for the analysis of genomic instability in colorectal cancer. **2010**, 693, 46-52 | 16 |

| 1980 | The DNA methylome of glioblastoma multiforme. **2010**, 39, 40-6 | 45 |

| 1979 | Human allelic variation: perspective from protein function, structure, and evolution. **2010**, 20, 342-50 | 56 |

| 1978 | Therapeutic targeting of p53 by small molecules. **2010**, 20, 46-56 | 67 |

| 1977 | Transposon-based screens for cancer gene discovery in mouse models. **2010**, 20, 261-8 | 25 |

| 1976 | Lethal mutagenesis: targeting the mutator phenotype in cancer. **2010**, 20, 353-9 | 61 |

1975   Statistical method on nonrandom clustering with application to somatic mutations in cancer. **2010**, 11, 11   46

1974   JISTIC: identification of significant targets in cancer. **2010**, 11, 189   38

1973   TumorBoost: normalization of allele-specific tumor copy numbers from a single pair of tumor-normal genotyping microarrays. **2010**, 11, 245   43

1972   A classification model for distinguishing copy number variants from cancer-related alterations. **2010**, 11, 297   13

1971   An integrated analysis of molecular aberrations in NCI-60 cell lines. **2010**, 11, 495   6

1970   Extracting consistent knowledge from highly inconsistent cancer gene data sources. **2010**, 11, 76   41

1969   The cost of reducing starting RNA quantity for Illumina BeadArrays: a bead-level dilution experiment. **2010**, 11, 540   4

1968   Investigation gene and microRNA expression in glioblastoma. **2010**, 11 Suppl 3, S16   33

1967   iCOD: an integrated clinical omics database based on the systems-pathology view of disease. **2010**, 11 Suppl 4, S19   22

1966   Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. **2010**, 60, 166-93   950

1965   Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. **2010**, 10, 91   66

1964   Notch signaling in glioblastoma: a developmental drug target?. **2010**, 8, 72   60

1963   Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma. **2010**, 4, 163   70

1962   An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer. **2010**, 4, 67   48

1961   Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. **2010**, 80, 755-61   28

1960   Numb--from flies to humans. **2010**, 32, 293-8   12

1959   Expression of targeting protein for Xenopus kinesin-like protein 2 is associated with progression of human malignant astrocytoma. **2010**, 1352, 200-7   28

1958   Interruption of β-catenin suppresses the EGFR pathway by blocking multiple oncogenic targets in human glioma cells. **2010**, 1366, 27-37   77

| 1957 | Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. **2010**, 17, 98-110 | 4782 |

| 1956 | Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. **2010**, 17, 510-22 | 1754 |

| 1955 | PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. **2010**, 17, 497-509 | 189 |

| 1954 | To infinium, and beyond!. **2010**, 17, 419-20 | 10 |

| 1953 | Integrative genomic profiling of human prostate cancer. **2010**, 18, 11-22 | 2666 |

| 1952 | In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. **2010**, 18, 244-57 | 203 |

| 1951 | Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. **2010**, 18, 619-29 | 183 |

| 1950 | Interpreting aCGH-defined karyotypic changes in gliomas using copy number status, loss of heterozygosity and allelic ratios. **2010**, 88, 82-9 | 4 |

| 1949 | The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer. **2010**, 116, 282-5 | 21 |

| 1948 | The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. **2010**, 117, 358-65 | 46 |

| 1947 | Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene. **2010**, 49, 509-17 | 20 |

| 1946 | Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. **2010**, 116, 4632-7 | 57 |

| 1945 | Chemistries for patterning robust DNA microbarcodes enable multiplex assays of cytoplasm proteins from single cancer cells. **2010**, 11, 3063-9 | 42 |

| 1944 | CanProVar: a human cancer proteome variation database. **2010**, 31, 219-28 | 55 |

| 1943 | Inferring the functional effects of mutation through clusters of mutations in homologous proteins. **2010**, 31, 264-71 | 38 |

| 1942 | alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. **2010**, 127, 1240-8 | 56 |

| 1941 | Characterization of ATP-induced cell death in the GL261 mouse glioma. **2010**, 109, 983-91 | 44 |

| 1940 | Sensing invasion: cell surface receptors driving spreading of glioblastoma. **2010**, 222, 1-10 | 63 |

1921	Analysis of the genome to personalize therapy for melanoma. **2010**, 29, 5545-55		105
1920	Whole-genome cancer analysis as an approach to deeper understanding of tumour biology. **2010**, 102, 243-8		8
1919	E17K substitution in AKT1 in prostate cancer. **2010**, 102, 1491-4		27
1918	Dissecting variability in responses to cancer chemotherapy through systems pharmacology. **2010**, 88, 34-8		46
1917	Mutated genes, pathways and processes in tumours. **2010**, 11, 805-10		27
1916	Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. **2010**, 24, 756-64		197
1915	A comprehensive catalogue of somatic mutations from a human cancer genome. *Nature*, **2010**, 463, 191-6	50.4	1303
1914	The transcriptional network for mesenchymal transformation of brain tumours. *Nature*, **2010**, 463, 318-25	50.4	890
1913	The landscape of somatic copy-number alteration across human cancers. *Nature*, **2010**, 463, 899-905	50.4	2590
1912	International network of cancer genome projects. *Nature*, **2010**, 464, 993-8	50.4	1613
1911	Cross-species genomics matches driver mutations and cell compartments to model ependymoma. *Nature*, **2010**, 466, 632-6	50.4	283
1910	Diverse somatic mutation patterns and pathway alterations in human cancers. *Nature*, **2010**, 466, 869-73	50.4	1003
1909	Glioblastoma stem-like cells give rise to tumour endothelium. *Nature*, **2010**, 468, 829-33	50.4	940
1908	The BioPAX community standard for pathway data sharing. **2010**, 28, 935-42		499
1907	Genomics boosts brain-cancer work. *Nature*, **2010**, 463, 278	50.4	9
1906	Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. **2010**, 42, 77-82		280
1905	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. **2010**, 42, 715-21		521
1904	An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. **2010**, 16, 286-94		311

1885	Systems Biology Approaches to Disease Marker Discovery. **2010**, 28, 209-224	17
1884	Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. **2010**, 2010, 251231	65
1883	Glioblastomas with Oligodendroglial Component □Common Origin of the Different Histological Parts and Genetic Subclassification. **2010**, 33, 37-54	15
1882	Allelic selection of amplicons in glioblastoma revealed by combining somatic and germline analysis. **2010**, 6, e1001086	21
1881	Automated network analysis identifies core pathways in glioblastoma. **2010**, 5, e8918	268
1880	DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. **2010**, 5, e9359	68
1879	Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. **2010**, 5, e9983	84
1878	Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. **2010**, 5, e10767	51
1877	Specific visualization of glioma cells in living low-grade tumor tissue. **2010**, 5, e11323	27
1876	Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. **2010**, 5, e11408	73
1875	Determining frequent patterns of copy number alterations in cancer. **2010**, 5, e12028	7
1874	Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL. **2010**, 5, e13552	38
1873	Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. **2010**, 5, e15661	169
1872	BeadDatapackR: A Tool to Facilitate the Sharing of Raw Data from Illumina BeadArray Studies. **2010**, 9, 117693511000900	1
1871	Phosphoinositide 3-Kinases. **2010**, 1049-1060	
1870	Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. **2010**, 48, 211-8	27
1869	The future role of personalized medicine in the treatment of glioblastoma multiforme. **2010**, 3, 111-27	12
1868	Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. **2010**, 107, 11501-6	165

1867	Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. **2010**, 28, 3061-8	468
1866	Familial aggregation of glioma: a pooled analysis. **2010**, 172, 1099-107	39
1865	MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. **2010**, 12, 822-33	65
1864	A compendium of genome-wide associations for cancer: critical synopsis and reappraisal. **2010**, 102, 846-58	58
1863	Role of phosphatidylinositol 3-kinase in friend spleen focus-forming virus-induced erythroid disease. **2010**, 84, 7675-82	8
1862	PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. **2010**, 24, 2205-18	152
1861	MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus. **2010**, 18, 1937-46	28
1860	The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. **2010**, 16, 6060-70	128
1859	A multigene predictor of outcome in glioblastoma. **2010**, 12, 49-57	274
1858	Evidence for and against regional differences in neural stem and progenitor cells of the CNS. **2010**, 24, 2233-8	6
1857	Protein microarrays for cancer diagnostics and therapy. **2010**, 19, 247-54	13
1856	Malignant astrocytomas: a system disease. **2010**, 67, 353-5	39
1855	Translating discovery to patient care. **2010**, 303, 1088-9	3
1854	Analysis of specialized DNA polymerases expression in human gliomas: association with prognostic significance. **2010**, 12, 679-86	66
1853	The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. **2010**, 31, 578-99	46
1852	A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. **2010**, 16, 3368-77	116
1851	Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma. **2010**, 9, 1638-46	34
1850	The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. **2010**, 70, 5305-15	105

1849	A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. **2010**, 70, 2158-64	67
1848	Clinical implications of the cancer genome. **2010**, 28, 5219-28	156
1847	Genetic risk profiles identify different molecular etiologies for glioma. **2010**, 16, 5252-9	48
1846	FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. **2010**, 70, 2951-61	62
1845	A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. **2010**, 38, e17	185
1844	Molecular evolutionary analysis of cancer cell lines. **2010**, 9, 279-91	8
1843	The value of 99mTc-tetrofosmin brain SPECT in predicting survival in patients with glioblastoma multiforme. **2010**, 51, 1923-6	16
1842	Bioluminescent approaches for measuring tumor growth in a mouse model of neurofibromatosis. **2010**, 38, 123-30	10
1841	Malignant Gliomas: Current Concepts. **2010**, 20, 115-121	
1840	Inhibition of the PI3K pathway: hope we can believe in?. **2010**, 16, 3094-9	34
1839	Knowledge-based data analysis comes of age. **2010**, 11, 30-9	14
1838	Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. **2010**, 23, 1404-17	147
1837	Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. **2010**, 28, 1345-50	124
1836	Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. **2010**, 70, 3228-38	223
1835	Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. **2010**, 70, 512-9	201
1834	Roles of fibroblast growth factor receptors in carcinogenesis. **2010**, 8, 1439-52	223
1833	Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. **2010**, 24, 1731-45	385
1832	Mig-6 controls EGFR trafficking and suppresses gliomagenesis. **2010**, 107, 6912-7	91

1831   Computational tools for the interactive exploration of proteomic and structural data. **2010**, 9, 1703-15   7

1830   O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. **2010**, 12, 283-8   99

1829   Oligodendrocyte progenitor cell numbers and migration are regulated by the zebrafish orthologs of the NF1 tumor suppressor gene. **2010**, 19, 4643-53   36

1828   Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies. **2010**, 16, 3431-41   44

1827   PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. **2010**, 12, 967-75   29

1826   Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. **2010**, 30, 35-51   236

1825   Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner. **2010**, 9, 1234-43   31

1824   Massively parallel signature sequencing and bioinformatics analysis identifies up-regulation of TGFBI and SOX4 in human glioblastoma. **2010**, 5, e10210   68

1823   Brain tumor stem cells maintain overall phenotype and tumorigenicity after in vitro culturing in serum-free conditions. **2010**, 12, 1220-30   45

1822   Emerging drugs to treat squamous cell carcinomas of the head and neck. **2010**, 15, 355-73   88

1821   A censored beta mixture model for the estimation of the proportion of non-differentially expressed genes. **2010**, 26, 640-6   20

1820   Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. **2010**, 12, 664-78   50

1819   Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome. **2010**, 16, 2890-8   25

1818   Interaction between 5 genetic variants and allergy in glioma risk. **2010**, 171, 1165-73   44

1817   Sensitivity to temozolomide in brain tumor initiating cells. **2010**, 12, 756-60   55

1816   Analysis of next-generation genomic data in cancer: accomplishments and challenges. **2010**, 19, R188-96   102

1815   Deep epistasis in human metabolism. **2010**, 20, 026104   12

1814   Bioprocessing of human glioblastoma brain cancer tissue. **2010**, 16, 1169-77   9

1813	Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. **2010**, 347, 279-96	96
1812	Protein kinase C: poised to signal. **2010**, 298, E395-402	395
1811	Regulatory subunits of class IA PI3K. **2010**, 346, 225-44	29
1810	Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. **2010**, 70, 7662-73	65
1809	Neuro-oncology: Genetic variation in pediatric and adult brain tumors. **2010**, 6, 653-4	4
1808	Current and emerging molecular targets in glioma. **2010**, 10, 1735-51	25
1807	Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers. **2010**, 4, 149-70	6
1806	Targeting miR-21 in glioma: a small RNA with big potential. **2010**, 14, 1247-57	41
1805	Therapeutic targeting of EGFR in malignant gliomas. **2010**, 14, 303-16	20
1804	Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. **2010**, 24, 2194-204	63
1803	Cancer sequencing gets a little more personal. **2010**, 2, 20ps8	1
1802	Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. **2010**, 12, 153-63	60
1801	Systematic interpretation of comutated genes in large-scale cancer mutation profiles. **2010**, 9, 2186-95	11
1800	Malignant Gliomas in Adults. **2010**, 36, 99-120	5
1799	Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. **2010**, 107, 5471-6	155
1798	New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. **2010**, 23, 856-65	64
1797	Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis. **2010**, 6, 1643-52	35
1796	Targeting the RB-pathway in cancer therapy. **2010**, 16, 1094-9	137

1795	Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. **2010**, 107, 1576-81	100
1794	Gene expression: protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer. **2010**, 70, 4809-19	34
1793	Systems Biology in Drug Discovery: Using Predictive Biomedicine to Guide Development Choices for Novel Agents in Cancer. **2010**, 399-414	1
1792	The nuclear receptor tailless induces long-term neural stem cell expansion and brain tumor initiation. **2010**, 24, 683-95	109
1791	Oncogenic mutations of PIK3CA in human cancers. **2010**, 347, 21-41	164
1790	Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein. **2010**, 107, 1954-9	84
1789	Allele-specific copy number analysis of tumors. **2010**, 107, 16910-5	699
1788	Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas. **2010**, 70, 3557-65	54
1787	Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. **2010**, 107, 15547-52	119
1786	Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. **2010**, 28, 2467-74	87
1785	Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. **2010**, 28, E6	40
1784	HHMD: the human histone modification database. **2010**, 38, D149-54	65
1783	Integrative platform to translate gene sets to networks. **2010**, 26, 1802-3	20
1782	PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling. **2010**, 12, 941-55	50
1781	Inherited predisposition to glioma. **2010**, 12, 104-13	56
1780	A quick guide to large-scale genomic data mining. **2010**, 6, e1000779	23
1779	The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme. **2010**, 9, 2618-26	32
1778	Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression. **2010**, 6, e1000899	291

1777	HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. **2010**, 12, 956-66	11
1776	Epigenetic biomarkers. **2012**, 355, 189-216	16
1775	Identifying tightly regulated and variably expressed networks by Differential Rank Conservation (DIRAC). **2010**, 6, e1000792	64
1774	Targeting A20 decreases glioma stem cell survival and tumor growth. **2010**, 8, e1000319	103
1773	HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. **2010**, 16, 474-85	267
1772	Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. **2010**, 70, 9730-41	43
1771	Genetic variations in EGF and EGFR and glioblastoma outcome. **2010**, 12, 815-21	17
1770	Targeted deep resequencing of the human cancer genome using next-generation technologies. **2010**, 27, 135-58	10
1769	The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E. **2010**, 9, 1451-2	27
1768	From man to mouse and back again: advances in defining tumor AKTivities in vivo. **2010**, 3, 705-20	13
1767	Emerging therapeutic targets and agents for glioblastoma migrating cells. **2010**, 10, 543-55	11
1766	Medical oncology: treatment and management of malignant gliomas. **2010**, 7, 75-7	19
1765	Pediatric brain tumors: genetics and clinical outcome. **2010**, 5, 263-70	20
1764	CMDS: a population-based method for identifying recurrent DNA copy number aberrations in cancer from high-resolution data. **2010**, 26, 464-9	49
1763	Genome-wide association studies: a powerful tool for neurogenomics. **2010**, 28, E2	6
1762	AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. **2010**, 9, 211-2	24
1761	Introduction. **2010**, 346, 1-7	3
1760	[Genetic and molecular abnormalities of glioblastomas (GBM)]. **2010**, 97, 1389-407	4

1741	Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials. **2010**, 20, 425-48	14
1740	Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. **2010**, 6, 1591-601	42
1739	Glioblastoma therapy: going beyond Hercules Columns. **2010**, 10, 507-14	40
1738	Glioma stem cell signaling: therapeutic opportunities and challenges. **2010**, 10, 709-22	30
1737	Cancer epigenome. **2010**, 70, 247-76	32
1736	Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. **2010**, 6, 1407-14	20
1735	Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. **2010**, 10, 1537-44	126
1734	PROBING CANCER SIGNALING WITH RESONANT WAVEGUIDE GRATING BIOSENSORS. **2010**, 5, 1237-1248	22
1733	Global changes of mRNA expression reveals an increased activity of the interferon-induced signal transducer and activator of transcription (STAT) pathway by repression of miR-221/222 in glioblastoma U251 cells. **2010**, 36, 1503-12	26
1732	Pathology and Classification of Tumors of the Nervous System. **2010**, 3-75	3
1731	Targeted Therapies. **2010**, 77-85	
1730	Translational Genomics. **2010**, 163-174	
1729	Tumors of the Nervous System. **2010**, 597-619	
1728	Whole genome sequencing. **2010**, 628, 215-26	116
1727	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. **2010**, 9, 135	203
1726	Personalized therapies in the cancer "omics" era. **2010**, 9, 202	39
1725	mTOR signaling in glioblastoma: lessons learned from bench to bedside. **2010**, 12, 882-9	124
1724	Integrative analysis of the melanoma transcriptome. **2010**, 20, 413-27	216

1723   A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. **2010**, 49, 767-75   59

1722   Molecular networks for the study of TCM pharmacology. **2010**, 11, 417-30   164

1721   Dysfunctional gene/protein networks in hepatitis C virus-induced hepatocellular cirrhosis and carcinoma. **2010**,   3

1720   Future of personalized medicine in oncology: a systems biology approach. **2010**, 28, 2777-83   195

1719   Mutational heterogeneity in human cancers: origin and consequences. **2010**, 5, 51-75   172

1718   [Glioblastoma: clinical, radiological and biological prognostic factors]. **2010**, 56, 467-76   7

1717   [Classification of glioblastoma and genome profiling]. **2010**, 56, 464-6

1716   [Glioblastomas: gliomagenesis, genetics, angiogenesis, and microenvironment]. **2010**, 56, 441-8   4

1715   Sorafenib exerts anti-glioma activity in vitro and in vivo. **2010**, 478, 165-70   63

1714   Signal transduction in the human thyrocyte and its perversion in thyroid tumors. **2010**, 321, 3-19   27

1713   Expectations, validity, and reality in omics. **2010**, 63, 945-9   44

1712   Catalogue, cause, complexity and cure; the many uses of cancer genome sequence. **2010**, 20, 336-41   4

1711   Gastrin-releasing peptide receptor content in human glioma and normal brain. **2010**, 82, 95-8   27

1710   Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. **2010**, 298, 139-49   77

1709   Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. **2010**, 13, 16-28   183

1708   Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. **2010**, 46, 2166-77   62

1707   Classification of adrenal cortical tumors: promise of the 'molecular' approach. **2010**, 24, 887-92   4

1706   The brothers RAF. **2010**, 140, 180-2   18

1705 NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. **2010**, 142, 218-29 — 151

1704 Unveiling the role of network and systems biology in drug discovery. **2010**, 31, 115-23 — 281

1703 Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip. **2010**, 52, 248-54 — 83

1702 EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. **2010**, 3, ra43 — 94

1701 Brain tumor stem cells: the cancer stem cell hypothesis writ large. **2010**, 4, 420-30 — 104

1700 Genome-wide association studies of cancer predisposition. **2010**, 24, 973-96 — 33

1699 Cancer systems biology: a network modeling perspective. **2010**, 31, 2-8 — 274

1698 MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. **2010**, 70, 9243-52 — 130

1697 U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. **2010**, 6, e1000832 — 195

1696 Genomic and biological characterization of exon 4 KRAS mutations in human cancer. **2010**, 70, 5901-11 — 218

1695 An Omics Perspective on Cancer Research. **2010**, — 9

1694 Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. **2010**, 107, 2183-8 — 185

1693 The Unfolded Protein Response, Degradation from Endoplasmic Reticulum and Cancer. **2010**, 1, 764-778 — 190

1692 Astrocytic and Oligodendroglial Tumors. **2010**, 63-102 — 4

1691 Genomics in the Management of Lymphomas. **2010**, 407-420

1690 Genomic Evaluation of Brain Tumors and Gliomas. **2010**, 522-531

1689 Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells. **2010**, 3, 50-5 — 21

1688 Trends in Applied Intelligent Systems. **2010**,

1687	Patient-oriented gene set analysis for cancer mutation data. **2010**, 11, R112	54
1686	A human functional protein interaction network and its application to cancer data analysis. **2010**, 11, R53	453
1685	Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme. **2010**, 2, 65	133
1684	Translational Medicine: Application of Omics for Drug Target Discovery and Validation. **2010**, 235-247	3
1683	The case for cloud computing in genome informatics. **2010**, 11, 207	339
1682	Somatic mutation of PIK3R1 gene is rare in common human cancers. **2010**, 49, 125-7	5
1681	A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. **2010**, 107, 17604-9	99
1680	Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. **2010**, 26, i237-45	537
1679	Bisulfite Patch PCR enables multiplexed sequencing of promoter methylation across cancer samples. **2010**, 20, 1279-87	52
1678	An integrative approach for in silico glioma research. **2010**, 57, 2617-21	49
1677	Investigating microRNA-transcription factor mediated regulatory network in glioblastoma. **2010**,	1
1676	PI3K: from the bench to the clinic and back. **2010**, 347, 1-19	57
1675	Structural effects of oncogenic PI3Kα mutations. **2010**, 347, 43-53	18
1674	NF-kappaB and STAT3 signaling in glioma: targets for future therapies. **2010**, 10, 575-86	103
1673	Bioinformatics and systems biology of cancers. **2010**, 95, 159-91	3
1672	Genome-wide DNA methylation analysis in tumor and normal tissues from lung squamous cell carcinoma and serous cystadenocarcinoma. **2010**,	
1671	Animal models for glioma drug discovery. **2011**, 6, 1271-83	12
1670	Pathway inhibition: emerging molecular targets for treating glioblastoma. **2011**, 13, 566-79	104

| 1669 | Gene-protein correlation in single cells. **2011**, 13, 880-5 | 3 |

| 1668 | Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. **2011**, 103, 714-36 | 508 |

| 1667 | BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. **2011**, 17, 4790-8 | 178 |

| 1666 | Integrative, multimodal analysis of glioblastoma using TCGA molecular data, pathology images, and clinical outcomes. **2011**, 58, 3469-74 | 47 |

| 1665 | An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. **2011**, 1, 442-56 | 258 |

| 1664 | Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays. **2011**, 13, 634-47 | 44 |

| 1663 | Algorithms for detecting significantly mutated pathways in cancer. **2011**, 18, 507-22 | 333 |

| 1662 | Evolution of clinical proteomics and its role in medicine. **2011**, 10, 66-84 | 46 |

| 1661 | Network modeling of the transcriptional effects of copy number aberrations in glioblastoma. **2011**, 7, 486 | 67 |

| 1660 | Nuclear factor I/B is an oncogene in small cell lung cancer. **2011**, 25, 1470-5 | 118 |

| 1659 | Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. **2011**, 108, 19024-9 | 81 |

| 1658 | p53 in the CNS: Perspectives on Development, Stem Cells, and Cancer. **2011**, 2, 431-42 | 43 |

| 1657 | Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of EGFR. **2011**, 10, 1343-52 | 37 |

| 1656 | A novel computational framework for simultaneous integration of multiple types of genomic data to identify microRNA-gene regulatory modules. **2011**, 27, i401-9 | 170 |

| 1655 | A comprehensive statistical model for cell signaling. **2011**, 8, 592-606 | 9 |

| 1654 | DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. **2011**, 21, 1017-27 | 179 |

| 1653 | Biomarqueurs pronostiques et facteurs prédictifs de la réponse au traitement dans les gliomes de l'adulte. **2011**, 2, 64-70 | 1 |

| 1652 | Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cells. **2011**, 13, 784-91 | 69 |

1651	Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase. **2011**, 51, 273-9		4
1650	DNA secondary structures and epigenetic determinants of cancer genome evolution. **2011**, 18, 950-5		169
1649	Selected Topics in the Molecular Pathology of Endometrial Carcinoma. **2011**, 4, 131-47		1
1648	Integrated genomic analyses of ovarian carcinoma. *Nature*, **2011**, 474, 609-15	50.4	5210
1647	SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. **2011**, 365, 2497-506		875
1646	Structural variation in two human genomes mapped at single-nucleotide resolution by whole genome de novo assembly. **2011**, 29, 723-30		99
1645	In vitro Selection of DNA Aptamers to Glioblastoma Multiforme. **2011**, 2, 175-181		88
1644	The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. **2011**, 43, 668-72		512
1643	Cancer epigenetics: linking basic biology to clinical medicine. **2011**, 21, 502-17		223
1642	[OMICS and biomarkers of glial tumors]. **2011**, 167, 691-8		2
1641	The pathological diagnosis of diffuse gliomas: towards a smart synthesis of microscopic and molecular information in a multidisciplinary context. **2011**, 17, 486-494		41
1640	Personalized medicine: progress and promise. **2011**, 12, 217-44		183
1639	Integration and analysis of genome-scale data from gliomas. **2011**, 7, 439-50		83
1638	The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors. **2011**, 10, 54		38
1637	MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma. **2011**, 30, 73		57
1636	Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas. **2011**, 30, 76		23
1635	Adenovirus-mediated delivery of bFGF small interfering RNA reduces STAT3 phosphorylation and induces the depolarization of mitochondria and apoptosis in glioma cells U251. **2011**, 30, 80		27
1634	Phosphoinositide 3-kinase in Health and Disease. **2011**,		

1633	Next generation sequencing has lower sequence coverage and poorer SNP-detection capability in the regulatory regions. **2011**, 1, 55	61
1632	Integrative genomics strategies to elucidate the complexity of drug response. **2011**, 12, 1695-715	25
1631	Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. **2011**, Chapter 14, Unit 14.16	140
1630	Algorithms in Bioinformatics. **2011**,	
1629	Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation. **2011**, 3, 2032-49	28
1628	CREST maps somatic structural variation in cancer genomes with base-pair resolution. **2011**, 8, 652-4	396
1627	Targeted Therapies. **2011**,	3
1626	Predictive, personalized, preventive, participatory (P4) cancer medicine. **2011**, 8, 184-7	464
1625	TP53 mutations in human cancer: database reassessment and prospects for the next decade. **2011**, 110, 107-39	57
1624	Phosphoinositide 3-kinase in Health and Disease. **2011**,	
1623	Integrating diverse genomic data using gene sets. **2011**, 12, R105	45
1622	GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. **2011**, 12, R41	1614
1621	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. **2011**, 43, 964-968	242
1620	Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas. **2011**, 11, 1759-74	22
1619	PDGF-B Can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation. **2011**, 13, 492-503	45
1618	Principles and strategies for developing network models in cancer. **2011**, 144, 864-73	149
1617	Mapping cancer origins. **2011**, 145, 25-9	30
1616	Mosaic analysis with double markers reveals tumor cell of origin in glioma. **2011**, 146, 209-21	461

| 1597 | Annotating individual human genomes. **2011**, 98, 233-41 | 17 |

| 1596 | Non-genomic loss of PTEN function in cancer: not in my genes. **2011**, 32, 131-40 | 122 |

| 1595 | Phosphorylation state of Olig2 regulates proliferation of neural progenitors. **2011**, 69, 906-17 | 90 |

| 1594 | Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. **2011**, 70, 898-907 | 509 |

| 1593 | Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. **2011**, 2, 180 | 765 |

| 1592 | The mutational landscape of head and neck squamous cell carcinoma. **2011**, 333, 1157-60 | 1836 |

| 1591 | Will kinase inhibitors make it as glioblastoma drugs?. **2012**, 355, 135-69 | 18 |

| 1590 | Chromosome 7p11.2 (EGFR) variation influences glioma risk. **2011**, 20, 2897-904 | 129 |

| 1589 | Unraveling the genetics of cancer: genome sequencing and beyond. **2011**, 12, 407-30 | 73 |

| 1588 | The origins of cancer robustness and evolvability. **2011**, 3, 17-30 | 114 |

| 1587 | Parsing out the complexity of RAF inhibitor resistance. **2011**, 24, 361-5 | 5 |

| 1586 | 'Omic approaches to preventing or managing metastatic breast cancer. **2011**, 13, 230 | 19 |

| 1585 | DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. **2011**, 29, 1103-8 | 129 |

| 1584 | New drugs for ovarian cancer. **2011**, 22 Suppl 8, viii77-viii82 | 7 |

| 1583 | Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. **2011**, 71, 7587-96 | 62 |

| 1582 | Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44. **2011**, 2, 457-463 | 30 |

| 1581 | Exposing The Cancer Genome Atlas (TCGA) as a SPARQL endpoint. **2011**, | |

| 1580 | High-order chromatin architecture determines the landscape of chromosomal alterations in cancer. **2011**, | 0 |

1579   Integrated Network Analysis of Genetic and Epigenetic Factors in Glioblastoma Multiform. **2011**,

1578   PHLPP1 (PH domain leucine-rich repeat protein phosphatase 1). **2011**,

1577   Performing quality research in an era of reforms. **2011**, 58, 72-8

1576   Human cancer classification: a systems biology- based model integrating morphology, cancer stem cells, proteomics, and genomics. **2011**, 2, 107-15   26

1575   Metabolism and brain cancer. **2011**, 66 Suppl 1, 33-43   75

1574   [MGMT analysis in gliomas]. **2011**, 98, 291-303   2

1573   Novel Perspectives on p53 Function in Neural Stem Cells and Brain Tumors. **2011**, 2011, 852970   21

1572   Differential Signature of the Centrosomal MARK4 Isoforms in Glioma. **2011**, 34, 319-338   15

1571   Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. **2011**, 4, 47   45

1570   Combined modality approaches in the management of adult glioblastoma. **2011**, 1, 36   6

1569   Animal models to study cancer-initiating cells from glioblastoma. **2011**, 16, 2243-58   17

1568   The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science. **2011**, 31, 61-71   31

1567   Overview and recent advances in neuropathology. Part 1: Central nervous system tumours. **2011**, 43, 88-92   12

1566   BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. **2011**, 6, e17948   228

1565   A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. **2011**, 6, e17649   95

1564   Unifying gene expression measures from multiple platforms using factor analysis. **2011**, 6, e17691   11

1563   Data integration workflow for search of disease driving genes and genetic variants. **2011**, 6, e18636   3

1562   Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. **2011**, 6, e20584   51

1561	Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression. **2011**, 6, e20605	66
1560	The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. **2011**, 6, e23332	76
1559	Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. **2011**, 6, e25451	204
1558	The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression. **2011**, 6, e25631	44
1557	Glioma surgery: a century of challenge. **2011**, 58, 7-9	6
1556	Multigene sets for clinical application in glioma. **2011**, 9, 449-56; quiz 457	5
1555	Glioma stem cell maintenance: the role of the microenvironment. **2011**, 17, 2386-401	67
1554	Epidermal growth factor receptor vaccination for glioblastoma multiforme. **2011**, 68, N20-1	1
1553	PTEN reconstitution alters glioma responses to c-Met pathway inhibition. **2011**, 22, 905-12	12
1552	Alteration in NFKBIA and EGFR in glioblastoma multiforme. **2011**, 68, N14-5	3
1551	Collateral damage control in cancer therapy: defining the stem identity in gliomas. **2011**, 17, 2370-85	1
1550	Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. **2011**, 118, 3080-7	218
1549	Advances in translational research in neuro-oncology. **2011**, 68, 303-8	4
1548	Identification and validation of a gene expression signature that predicts outcome in malignant glioma patients. **2012**, 40, 721-30	5
1547	Traveling waves of selective sweeps. **2011**, 21,	14
1546	A novel potent tumour promoter aberrantly overexpressed in most human cancers. **2011**, 1, 15	13
1545	Novel clinical trials in neuro-oncology. **2011**, 1, 781-794	1
1544	Central nervous system. **2010**, 9, 193-210	28

1543　Remarkable difference of somatic mutation patterns between oncogenes and tumor suppressor genes. **2011**, 26, 1539-46　　4

1542　False discovery rates in somatic mutation studies of cancer. **2011**, 5,　　6

1541　Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells. **2011**, 38, 555-69　　25

1540　Development of a phylogenetic tree model to investigate the role of genetic mutations in endometrial tumors. **2011**, 25, 1447-54　　28

1539　DJ-1 expression in glioblastomas shows positive correlation with p53 expression and negative correlation with epidermal growth factor receptor amplification. **2011**, 31, 29-37　　22

1538　Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study. **2011**, 31, 583-8　　28

1537　Carboxyl terminus of Hsp70-interacting protein (CHIP) contributes to human glioma oncogenesis. **2011**, 102, 959-66　　30

1536　Cancer epigenetics reaches mainstream oncology. **2011**, 17, 330-9　　920

1535　Cancer genomics: from discovery science to personalized medicine. **2011**, 17, 297-303　　415

1534　A close look at cancer. **2011**, 17, 262-5　　7

1533　Research Highlights. **2011**, 17, 294-295

1532　Cyclin D as a therapeutic target in cancer. **2011**, 11, 558-72　　969

1531　What does physics have to do with cancer?. **2011**, 11, 657-70　　143

1530　A decade of exploring the cancer epigenome - biological and translational implications. **2011**, 11, 726-34　　2002

1529　Cancer research: past, present and future. **2011**, 11, 749-54　　119

1528　Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. **2011**, 30, 1341-50　　32

1527　Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. **2011**, 30, 2433-42　　117

1526　Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. **2011**, 104, 545-53　　85

1525	Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. **2011**, 91, 1068-78		38
1524	The genomic complexity of primary human prostate cancer. *Nature*, **2011**, 470, 214-20	50.4	984
1523	Charting a course for genomic medicine from base pairs to bedside. *Nature*, **2011**, 470, 204-13	50.4	677
1522	Integrative genomics viewer. **2011**, 29, 24-6		7463
1521	Abl interconnects oncogenic Met and p53 core pathways in cancer cells. **2011**, 18, 1608-16		53
1520	The use of global profiling in biomarker development for gliomas. **2011**, 21, 88-95		17
1519	Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations. **2011**, 21, 645-51		28
1518	Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies. **2011**, 21, 479-500		16
1517	Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. **2011**, 15, 2735-44		67
1516	Genome-wide approaches for cancer gene discovery. **2011**, 29, 558-68		25
1515	Analysis of cancer signaling networks by systems biology to develop therapies. **2011**, 21, 200-6		25
1514	Neuro-oncology: continuing multidisciplinary progress. **2011**, 10, 18-20		6
1513	Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. **2011**, 38, 243-53		59
1512	Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. **2011**, 38, 173-85		49
1511	The impact of recent data on the optimization of standards of care in newly diagnosed glioblastoma. **2011**, 38 Suppl 4, S11-20		15
1510	Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. **2011**, 317, 1476-89		42
1509	Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. **2011**, 123, 5-12		63
1508	Integrative set enrichment testing for multiple omics platforms. **2011**, 12, 459		7

1489 The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations. **2011**, 30, 199-210   57

1488 The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells. **2011**, 102, 353-66   28

1487 Whole-genomic survey of oligodendroglial tumors: correlation between allelic imbalances and gene expression profiles. **2011**, 103, 71-85   4

1486 PI3Kinase signaling in glioblastoma. **2011**, 103, 417-27   56

1485 Cancer susceptibility variants and the risk of adult glioma in a US case-control study. **2011**, 104, 535-42   68

1484 Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. **2011**, 130, 93-101   12

1483 Somatic variation and cancer: therapies lost in the mix. **2011**, 130, 79-91   34

1482 Current status of genome-wide association studies in cancer. **2011**, 130, 59-78   142

1481 Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas. **2011**, 121, 529-43   14

1480 PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma. **2011**, 121, 407-20   107

1479 Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. **2011**, 122, 495-510   101

1478 Loss of heterozygosity analysis in malignant gliomas. **2011**, 28, 191-6   18

1477 Molecular and clinical analysis of glioblastoma with an oligodendroglial component (GBMO). **2011**, 28, 185-90   21

1476 Expression of stem cell marker and receptor kinase genes in glioblastoma tissue quantified by real-time RT-PCR. **2011**, 28, 291-6   24

1475 New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status. **2011**, 28, 203-8   6

1474 Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression. **2011**, 31, 9-15   48

1473 Gene expression profiling of meningiomas: current status after a decade of microarray-based transcriptomic studies. **2011**, 153, 447-56   12

1472 Chemotherapie bei Gliomen. **2011**, 17, 44-54   1

| 1453 | Combinations of newly confirmed Glioma-Associated loci link regions on chromosomes 1 and 9 to increased disease risk. **2011**, 4, 63 | 17 |

| 1452 | Functional characterization of Trip10 in cancer cell growth and survival. **2011**, 18, 12 | 18 |

| 1451 | Detection of recurrent rearrangement breakpoints from copy number data. **2011**, 12, 114 | 20 |

| 1450 | The PathOlogist: an automated tool for pathway-centric analysis. **2011**, 12, 133 | 28 |

| 1449 | A motif-independent metric for DNA sequence specificity. **2011**, 12, 408 | 15 |

| 1448 | Semantically enabled and statistically supported biological hypothesis testing with tissue microarray databases. **2011**, 12 Suppl 1, S51 | 2 |

| 1447 | Clinical cancer genomics: how soon is now?. **2011**, 223, 318-26 | 30 |

| 1446 | KRAS and BRAF: drug targets and predictive biomarkers. **2011**, 223, 219-29 | 115 |

| 1445 | Combination of a ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells. **2011**, 29, 590-9 | 33 |

| 1444 | p53 directly represses Id2 to inhibit the proliferation of neural progenitor cells. **2011**, 29, 1090-101 | 33 |

| 1443 | MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. **2011**, 29, 1942-51 | 70 |

| 1442 | Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. **2011**, 103, 773-81 | 27 |

| 1441 | Exploring genomic profiles of hepatocellular carcinoma. **2011**, 50, 235-43 | 55 |

| 1440 | Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. **2011**, 24, 734-49 | 74 |

| 1439 | Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. **2011**, 59, 1205-12 | 26 |

| 1438 | Genetic modeling of gliomas in mice: new tools to tackle old problems. **2011**, 59, 1155-68 | 79 |

| 1437 | The origins of glioma: E Pluribus Unum?. **2011**, 59, 1135-47 | 65 |

| 1436 | Drosophila melanogaster as a model system for human brain cancers. **2011**, 59, 1364-76 | 34 |

1435	Molecular subclassification of diffuse gliomas: seeing order in the chaos. **2011**, 59, 1190-9	180
1434	Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. **2011**, 59, 1148-54	110
1433	High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. **2011**, 50, 397-408	86
1432	Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. **2011**, 50, 606-18	72
1431	Benefits of interferon-α and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. **2011**, 117, 1721-30	72
1430	Cancer genome variation in children, adolescents, and young adults. **2011**, 117, 2262-7	4
1429	Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma. **2011**, 32, E2148-75	32
1428	Analysis of pathway mutation profiles highlights collaboration between cancer-associated superpathways. **2011**, 32, 1028-35	9
1427	Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. **2011**, 128, 787-96	19
1426	Molecular signatures classify astrocytic gliomas by IDH1 mutation status. **2011**, 128, 1095-103	64
1425	Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. **2011**, 128, 1981-8	41
1424	Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. **2011**, 129, 659-70	213
1423	Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. **2011**, 30, E7	41
1422	Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. **2011**, 18, 2674-85	55
1421	Therapeutic strategies to target multiple kinases in glioblastoma. **2011**, 11, 700-11	7
1420	Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. **2011**, 21, 665-75	68
1419	Pediatric brain tumor cancer stem cells: cell cycle dynamics, DNA repair, and etoposide extrusion. **2011**, 13, 70-83	50
1418	Genomic alterations and the pathogenesis of glioblastoma. **2011**, 10, 1174-5	3

1417	The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors. **2011**, 11, 894-918	27
1416	Discovering neurosurgery: new frontiers. **2011**, 115, 1053-66	0
1415	Posttranscriptional regulation of the p85 adapter subunit of phosphatidylinositol 3-kinase in human leukemia cells. **2011**, 52, 467-77	2
1414	Unifying cancer genetics. **2011**, 13, 203-4	1
1413	Gene expression analysis with integrated fuzzy C-means and pathway analysis. **2011**, 2011, 936-9	3
1412	FoxO family members in cancer. **2011**, 12, 253-9	120
1411	Challenging issues in pediatric oncology. **2011**, 8, 540-9	149
1410	DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. **2011**, 103, 143-53	194
1409	New phosphatidylinositol 3-kinase inhibitors for cancer. **2011**, 20, 507-18	48
1408	MicroRNA-146a inhibits glioma development by targeting Notch1. **2011**, 31, 3584-92	150
1407	RAS Interaction with PI3K: More Than Just Another Effector Pathway. **2011**, 2, 261-74	463
1406	Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. **2011**, 108, E1128-36	163
1405	MORPHOLOGICAL SIGNATURES AND GENOMIC CORRELATES IN GLIOBLASTOMA. **2011**, 1624-1627	17
1404	Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRA **2011**, 10, 1407-18	39
1403	Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. **2011**, 71, 6061-72	274
1402	Immunotherapy for glioblastoma: the devil is in the details. **2011**, 29, 3105; author reply 3105-6	10
1401	Parent-specific copy number in paired tumor-normal studies using circular binary segmentation. **2011**, 27, 2038-46	76
1400	Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation. **2011**, 71, 7198-206	23

1399	Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. **2011**, 71, 106-15	24
1398	Losing balance: Hardy-Weinberg disequilibrium as a marker for recurrent loss-of-heterozygosity in cancer. **2011**, 20, 4831-9	4
1397	NFKBIA deletion in glioblastomas. **2011**, 364, 627-37	188
1396	Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment. **2011**, 17, 7563-73	52
1395	Integrative cancer genomics (IntOGen) in Biomart. **2011**, 2011, bar039	16
1394	A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. **2011**, 17, 3686-96	63
1393	Targeted therapy for BRAFV600E malignant astrocytoma. **2011**, 17, 7595-604	128
1392	Online resources of cancer data: barriers, benefits and lessons. **2011**, 12, 52-63	17
1391	A new frontier in personalized cancer therapy: mapping molecular changes. **2011**, 7, 873-94	12
1390	Making sense of cancer genomic data. **2011**, 25, 534-55	260
1389	Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells. **2011**, 108, 12384-9	33
1388	Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype. **2011**, 71, 6643-53	105
1387	The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. **2011**, 13, 736-47	76
1386	NKX2.2 suppresses self-renewal of glioma-initiating cells. **2011**, 71, 1135-45	19
1385	Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas. **2011**, 13, 42-50	33
1384	Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. **2011**, 13, 1178-91	64
1383	Report from the fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop. **2011**, 13, 692-9	6
1382	Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. **2011**, 208, 2657-73	50

1381	Multi-platform segmentation for joint detection of copy number variants. **2011**, 27, 1555-61	6
1380	Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies. **2011**, 13, 610-21	29
1379	Deciphering squamous cell carcinoma using multidimensional genomic approaches. **2011**, 2011, 541405	7
1378	Genetics of glioblastoma: a window into its imaging and histopathologic variability. **2011**, 31, 1717-40	36
1377	Molecular cytogenetic analysis of a gliosarcoma with osseous metaplasia. **2011**, 134, 88-95	3
1376	Stress-induced modulators of repeat instability and genome evolution. **2011**, 21, 36-44	24
1375	Neurooncology. **2011**, 39, 124-8	1
1374	Connective tissue growth factor and the parallels between brain injury and brain tumors. **2011**, 103, 1141-3	9
1373	Comprehensive exon array data processing method for quantitative analysis of alternative spliced variants. **2011**, 39, e123	24
1372	Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. **2011**, 13, 84-98	99
1371	A bioinformatics workflow for variant peptide detection in shotgun proteomics. **2011**, 10, M110.006536	73
1370	Penalized regression elucidates aberration hotspots mediating subtype-specific transcriptional responses in breast cancer. **2011**, 27, 2679-85	2
1369	Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. **2011**, 71, 4550-61	122
1368	PIK3R1 (p85 is somatically mutated at high frequency in primary endometrial cancer. **2011**, 71, 4061-7	166
1367	Platelet-derived growth factor receptor alpha in glioma: a bad seed. **2011**, 30, 590-602	30
1366	TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. **2011**, 64, 850-2	55
1365	RAD51 can inhibit PDGF-B-induced gliomagenesis and genomic instability. **2011**, 13, 1277-87	9
1364	Stem cells in brain tumor development. **2011**, 94, 15-44	13

1363 A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. **2011**, 208, 689-702   65

1362 Targeting oncogenic protein-protein interactions by diversity oriented synthesis and combinatorial chemistry approaches. **2011**, 16, 4408-27   18

1361 Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model. **2011**, 71, 4106-16   54

1360 Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. **2011**, 13, 212-22   92

1359 Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. **2011**, 15, 829-46   42

1358 Towards tailored therapy of glioblastoma multiforme. **2011**, 23, 187-99   16

1357 Gene regulation in glioblastoma: a combinatorial analysis of microRNAs and transcription factors. **2011**, 4, 111-26   3

1356 Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome. **2011**, 6, 317-25   77

1355 Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. **2011**, 10, 33-8   62

1354 Role and relevance of TrkB mutations and expression in non-small cell lung cancer. **2011**, 17, 2638-45   40

1353 Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. **2011**, 1, 524-38   218

1352 Mislocalization of the E3 ligase, β-transducin repeat-containing protein 1 (βTrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt. **2011**, 286, 19777-88   36

1351 Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. **2011**, 108, 15996-6001   73

1350 Human glioma growth is controlled by microRNA-10b. **2011**, 71, 3563-72   236

1349 Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. **2011**, 29, 3999-4006   228

1348 Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. **2011**, 13, e17   214

1347 Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. **2011**, 10, 2405-14   83

1346 A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. **2011**, 10, 1818-28   64

1345	Epithelial phosphatidylinositol-3-kinase signaling is required for catenin activation and host defense against Citrobacter rodentium infection. **2011**, 79, 1863-72	36
1344	WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. **2011**, 17, 4200-7	170
1343	Reply to M.S. Lesniak. **2011**, 29, 3105-3106	9
1342	COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. **2011**, 39, D945-50	1774
1341	MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-signaling pathway in human glioblastoma. **2011**, 71, 2392-402	105
1340	Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma. **2011**, 105, 1235-43	19
1339	Advances in malignant glioma drug discovery. **2011**, 6, 739-53	15
1338	Novel ways to target brain tumour metabolism. **2011**, 15, 1227-39	12
1337	. **2011**,	4
1336	Role of tyrosine kinase inhibitors in the management of high-grade gliomas. **2011**, 11, 1739-48	3
1335	NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor. **2011**, 10, 3284-99	30
1334	Predicting the functional impact of protein mutations: application to cancer genomics. **2011**, 39, e118	1237
1333	Gene Coexpression Networks for the Analysis of DNA Microarray Data. **2011**, 215-250	31
1332	DNA damage response and repair: insights into strategies for radiation sensitization of gliomas. **2011**, 7, 1335-46	32
1331	Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. **2011**, 13, 384-92	118
1330	A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. **2011**, 108, 1591-6	94
1329	A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. **2011**, 71, 3387-99	154
1328	Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. **2011**, 2011, bar018	41

1327 Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. **2011**, 13, 367-75 26

1326 Genetic alterations in glioma. **2011**, 3, 1129-40 19

1325 Cancer Systems Biology. **2011**, 533-565 1

1324 Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. **2011**, 30, 4084-97 110

1323 CNAmet: an R package for integrating copy number, methylation and expression data. **2011**, 27, 887-8 71

1322 International Cancer Genome Consortium Data Portal--a one-stop shop for cancer genomics data. **2011**, 2011, bar026 382

1321 The UCSC Cancer Genomics Browser: update 2011. **2011**, 39, D951-9 49

1320 NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature. **2011**, 13, 830-45 51

1319 Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma. **2011**, 80, 1076-84 23

1318 C/EBPexpression is downregulated in human nonmelanoma skin cancers and inactivation of C/EBPconfers susceptibility to UVB-induced skin squamous cell carcinomas. **2011**, 131, 1339-46 14

1317 High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. **2011**, 1, 170-85 342

1316 Estimation of parent specific DNA copy number in tumors using high-density genotyping arrays. **2011**, 7, e1001060 34

1315 Aberrant signaling pathways in glioma. **2011**, 3, 3242-78 125

1314 It is time to include patients with brain tumors in phase I trials in oncology. **2011**, 29, 3211-3 20

1313 Bayesian ensemble methods for survival prediction in gene expression data. **2011**, 27, 359-67 42

1312 EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. **2011**, 71, 7125-34 108

1311 dbDEPC 2.0: updated database of differentially expressed proteins in human cancers. **2012**, 40, D964-71 17

1310 Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12. **2012**, 14, 160-74 20

| 1309 | Uncovering MicroRNA and Transcription Factor Mediated Regulatory Networks in Glioblastoma. **2012**, 8, e1002488 | 110 |

| 1308 | Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. **2012**, 19, 428-39 | 96 |

| 1307 | Comparative genomic analysis of primary versus metastatic colorectal carcinomas. **2012**, 30, 2956-62 | 225 |

| 1306 | Strategies for annotation and curation of translational databases: the eTUMOUR project. **2012**, 2012, bas035 | 15 |

| 1305 | p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. **2012**, 14, 870-81 | 120 |

| 1304 | Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. **2012**, 8, e1002772 | 385 |

| 1303 | Integrins and p53 pathways in glioblastoma resistance to temozolomide. **2012**, 2, 157 | 22 |

| 1302 | MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma. **2012**, 18, 3030-41 | 36 |

| 1301 | Molecularly targeted therapy in neuro-oncology. **2012**, 104, 255-78 | 8 |

| 1300 | Granulocyte-colony stimulating factor promotes proliferation, migration and invasion in glioma cells. **2012**, 13, 389-400 | 40 |

| 1299 | SNP Discovery through Next-Generation Sequencing and Its Applications. **2012**, 2012, 831460 | 170 |

| 1298 | Differential network entropy reveals cancer system hallmarks. **2012**, 2, 802 | 111 |

| 1297 | Key concepts in glioblastoma therapy. **2012**, 83, 753-60 | 59 |

| 1296 | Direct inhibition of myosin II effectively blocks glioma invasion in the presence of multiple motogens. **2012**, 23, 533-42 | 80 |

| 1295 | Integrative analysis of gene and miRNA expression profiles with transcription factor-miRNA feed-forward loops identifies regulators in human cancers. **2012**, 40, e135 | 68 |

| 1294 | Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells. **2012**, 109, E2998-3007 | 52 |

| 1293 | Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. **2012**, 14, 315-25 | 76 |

| 1292 | A common ancestry for BAP1 and Uch37 regulators. **2012**, 28, 1953-6 | 40 |

1291   La formalisation de la GRH dans une PME comme enjeu d'une certification RSE. **2012**, 83, 20   6

1290   SurvNet: a web server for identifying network-based biomarkers that most correlate with patient survival data. **2012**, 40, W123-6   20

1289   Management of malignant gliomas and primary CNS lymphoma: standard of care and future directions. **2012**, 18, 406-15   8

1288   Individualized targeted therapy for glioblastoma: fact or fiction?. **2012**, 18, 40-4   57

1287   The molecular basis for novel therapies. **2012**, 18, 32-9   3

1286   Reverse engineering biomolecular systems using -omic data: challenges, progress and opportunities. **2012**, 13, 430-45   17

1285   Network of Cancer Genes (NCG 3.0): integration and analysis of genetic and network properties of cancer genes. **2012**, 40, D978-83   31

1284   Current clinical development of PI3K pathway inhibitors in glioblastoma. **2012**, 14, 819-29   105

1283   A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. **2012**, 18, 4173-82   136

1282   Prioritizing cancer-related key miRNA-target interactions by integrative genomics. **2012**, 40, 7653-65   29

1281   Integrative functional genomics identifies RINT1 as a novel GBM oncogene. **2012**, 14, 1325-31   12

1280   Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. **2012**, 21, 5406-16   85

1279   Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. **2012**, 21, 5397-405   111

1278   Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. **2012**, 40, 6725-40   114

1277   Biological Interpretation of Morphological Patterns in Histopathological Whole-Slide Images. **2012**, 2012, 218-225   42

1276   Fine mapping analysis of a region of 20q13.33 identified five independent susceptibility loci for glioma in a Chinese Han population. **2012**, 33, 1065-71   21

1275   Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. **2012**, 4, 157ra143   277

1274   Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling. **2012**, 287, 3610-6   54

1273	N-cadherin expression level modulates integrin-mediated polarity and strongly impacts on the speed and directionality of glial cell migration. **2012**, 125, 844-57	96
1272	The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. **2012**, 72, 5878-88	113
1271	Rare TP53 genetic variant associated with glioma risk and outcome. **2012**, 49, 420-1	33
1270	Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets. **2012**, 22, 386-97	77
1269	Therapeutic Kinase Inhibitors. **2012**,	1
1268	Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. **2012**, 109, 570-5	96
1267	SSBP2 variants are associated with survival in glioblastoma patients. **2012**, 18, 3154-62	18
1266	Efficacy and safety of bevacizumab in glioblastomas. **2012**, 19, 972-81	12
1265	Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. **2012**, 19, 5735-44	41
1264	SEQanswers: an open access community for collaboratively decoding genomes. **2012**, 28, 1272-3	49
1263	Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. **2012**, 5, 881-94	58
1262	Molecular prescreening to select patient population in early clinical trials. **2012**, 9, 359-66	52
1261	Identifying multi-layer gene regulatory modules from multi-dimensional genomic data. **2012**, 28, 2458-66	94
1260	Calling amplified haplotypes in next generation tumor sequence data. **2012**, 22, 362-74	8
1259	Genomic complexity and AKT dependence in serous ovarian cancer. **2012**, 2, 56-67	89
1258	Sapacitabine for cancer. **2012**, 21, 541-55	17
1257	Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?. **2012**, 1, 137-48	5
1256	Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. **2012**, 12, 197-209	159

| 1237 | A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. **2012**, 2, 140-55 | 90 |

| 1236 | Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. **2012**, 14, 1511-8 | 82 |

| 1235 | FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. **2012**, 2, 1118-33 | 252 |

| 1234 | Passenger mutations take the wheel. **2012**, 5, 915-915 | |

| 1233 | Disruption of Abi1/Hssh3bp1 expression induces prostatic intraepithelial neoplasia in the conditional Abi1/Hssh3bp1 KO mice. **2012**, 1, e26 | 12 |

| 1232 | Translational genomics: the challenge of developing cancer biomarkers. **2012**, 22, 183-7 | 70 |

| 1231 | Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer. **2012**, 287, 8048-59 | 24 |

| 1230 | Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells. **2012**, 287, 9962-9971 | 147 |

| 1229 | Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. **2012**, 109, 14164-9 | 85 |

| 1228 | Targeting JNK for therapeutic depletion of stem-like glioblastoma cells. **2012**, 2, 516 | 54 |

| 1227 | Toward a better dialogue between neuro-oncologists and phase I investigators. **2012**, 30, 562-3; author reply 563-4 | 2 |

| 1226 | Definition of genetic events directing the development of distinct types of brain tumors from postnatal neural stem/progenitor cells. **2012**, 72, 3381-92 | 12 |

| 1225 | Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. **2012**, 109, 19368-73 | 95 |

| 1224 | Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. **2012**, 109, 3018-23 | 81 |

| 1223 | Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. **2012**, 72, 4383-93 | 204 |

| 1222 | Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival. **2012**, 72, 2543-53 | 62 |

| 1221 | Discovery in context: leveraging multidimensional glioblastoma datasets to identify targetable regulatory networks. **2012**, 2, 676-8 | 1 |

| 1220 | Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma. **2012**, 109, 4251-6 | 64 |

1201   Moving toward molecular classification of diffuse gliomas in adults. **2012**, 79, 1917-26   54

1200   Functional impact bias reveals cancer drivers. **2012**, 40, e169   238

1199   On the origin of glioma. **2012**, 117, 113-21   51

1198   Integrated Analysis Reveals hsa-miR-142 as a Representative of a Lymphocyte-Specific Gene Expression and Methylation Signature. **2012**, 11, 61-75   17

1197   Disease biology in the coming decade(s). **2012**, 19, 149-50   1

1196   Current trends in targeted therapies for glioblastoma multiforme. **2012**, 2012, 878425   102

1195   Catenin Signalling in Glioblastoma Multiforme and Glioma-Initiating Cells. **2012**, 2012, 192362   57

1194   Beyond Genetics in Glioma Pathways: The Ever-Increasing Crosstalk between Epigenomic and Genomic Events. **2012**, 2012, 519807   11

1193   Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. **2012**, 2, 186   67

1192   Monoallelic expression determines oncogenic progression and outcome in benign and malignant brain tumors. **2012**, 72, 636-44   40

1191   Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. **2012**, 448, 417-23   137

1190   Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. **2012**, 287, 14012-22   17

1189   Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. **2012**, 26, 1247-62   75

1188   Mutual exclusivity analysis identifies oncogenic network modules. **2012**, 22, 398-406   452

1187   Studying a complex tumor: potential and pitfalls. **2012**, 18, 107-14   23

1186   JointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal/tumour paired next-generation sequencing data. **2012**, 28, 907-13   136

1185   Inhibition and termination of physiological responses by GTPase activating proteins. **2012**, 92, 237-72   41

1184   Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. **2012**, 4, 116ra4   297

1183 Targeted therapeutic strategies for relapsed disease. **2012**, 28-40

1182 KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas. **2012**, 135, 1027-41   37

1181 Using large-scale molecular data sets to improve breast cancer treatment. **2012**, 1, 57-64   2

1180 MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. **2012**, 5, rs4   31

1179 Genomic estimates of aneuploid content in glioblastoma multiforme and improved classification. **2012**, 18, 5595-605   26

1178 Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma. **2012**, 41, 1260-70   37

1177 Cell of origin determines tumor phenotype in an oncogenic Ras/p53 knockout transgenic model of high-grade glioma. **2012**, 71, 729-40   15

1176 Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field ofClinical Practice. **2012**, 9, 241-246

1175 Thérapies moléculaires ciblées et antiangiogéniques dans le traitement des glioblastomes. **2012**, 9, 1-13

1174 BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. **2012**, 71, 66-72   129

1173 Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype. **2012**, 71, 83-9   37

1172 DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome. **2012**, 71, 702-7   14

1171 BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. **2012**, 71, 789-94   51

1170 Identification of disease-relevant genes for molecularly-targeted drug discovery. **2012**, 12, 1-13   9

1169 Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer. **2012**, 22, 725-31   10

1168 Cancer immunoediting in malignant glioma. **2012**, 71, 201-22; discussion 222-3   62

1167 EGFR targeted inhibition resistance: compensatory activation of ERBB family members in glioblastoma cancer stem-like cells promotes proliferation. **2012**, 71, N17-8   1

1166 Transcriptional Analysis of JAK/STAT Signaling in Glioblastoma Multiforme. **2012**, 10,   0

| 1165 | Identification of prognostic biomarkers for glioblastomas using protein expression profiling. **2012**, 40, 1122-32 | 17 |

| 1164 | TP53 codon 72 polymorphism and glioma risk: A meta-analysis. **2012**, 3, 599-606 | 12 |

| 1163 | Targeting PI3 kinase/AKT/mTOR signaling in cancer. **2012**, 17, 69-95 | 176 |

| 1162 | . | 1 |

| 1161 | Estimation of a non-parametric variable importance measure of a continuous exposure. **2012**, 6, 1059-1099 | 13 |

| 1160 | Casein kinase 2 inhibition modulates the DNA damage response but fails to radiosensitize malignant glioma cells. **2012**, 41, 776-82 | 12 |

| 1159 | Network biology of tumor stem-like cells identified a regulatory role of CBX5 in lung cancer. **2012**, 2, 584 | 39 |

| 1158 | The p85 regulatory subunit of PI3K mediates cAMP-PKA and retinoic acid biological effects on MCF7 cell growth and migration. **2012**, 40, 1627-35 | 12 |

| 1157 | Cancer and the Use of Biosensors for Cancer Clinical Testing. **2012**, 3-40 | 1 |

| 1156 | Glioma and Other Neuroepithelial Neoplasms. **2012**, 767-794 | |

| 1155 | Primary brain tumours in adults. **2012**, 379, 1984-96 | 447 |

| 1154 | The cancer epigenome: its origins, contributions to tumorigenesis, and translational implications. **2012**, 9, 64-5 | 43 |

| 1153 | Differential expression of 2',3'-cyclic-nucleotide 3'-phosphodiesterase and neural lineage markers correlate with glioblastoma xenograft infiltration and patient survival. **2012**, 18, 3628-36 | 34 |

| 1152 | integIRTy: a method to identify genes altered in cancer by accounting for multiple mechanisms of regulation using item response theory. **2012**, 28, 2861-9 | 5 |

| 1151 | Efficient methods for identifying mutated driver pathways in cancer. **2012**, 28, 2940-7 | 109 |

| 1150 | Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. **2012**, 104, 1458-69 | 45 |

| 1149 | Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. **2012**, 18, 1835-40 | 521 |

| 1148 | microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. **2012**, 2, 736-49 | 90 |

1147   Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. **2012**, 103, 1871-9   32

1146   Cancer genomics and pathology: all together now. **2012**, 62, 647-59   5

1145   The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. **2012**, 2, 401-4   8578

1144   Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. **2012**, 11, 489-502   53

1143   Prospective, high-throughput molecular profiling of human gliomas. **2012**, 110, 89-98   44

1142   Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results. **2012**, 21, 1391-415   50

1141   Neurofibromatosis type 1: modeling CNS dysfunction. **2012**, 32, 14087-93   66

1140   Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. **2012**, 22, 547-60   319

1139   Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. **2012**, 30, e30-3   95

1138   Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. **2012**, 109, 419-24   262

1137   Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts. **2012**, 11, 1724-40   68

1136   Glioblastoma multiforme: overview of current treatment and future perspectives. **2012**, 26, 825-53   105

1135   Nanotechnology applications for glioblastoma. **2012**, 23, 439-49   22

1134   Genome-wide association study of glioma and meta-analysis. **2012**, 131, 1877-88   191

1133   Emerging real-time technologies in molecular medicine and the evolution of integrated 'pharmacomics' approaches to personalized medicine and drug discovery. **2012**, 136, 295-304   11

1132   Nanoparticle-Based Delivery of siRNA and miRNA for Cancer Therapy. **2012**, 185-203   3

1131   Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. **2012**, 72, 3350-9   73

1130   Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. **2012**, 124, 615-25   295

| 1129 | 53BP1 is a haploinsufficient tumor suppressor and protects cells from radiation response in glioma. **2012**, 72, 5250-60 | 24 |

| 1128 | Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. **2012**, 72, 2657-71 | 43 |

| 1127 | D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. **2012**, 26, 2038-49 | 218 |

| 1126 | SPRED proteins provide a NF-ty link to Ras suppression. **2012**, 26, 1515-9 | 9 |

| 1125 | Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. **2012**, 2, 458-71 | 240 |

| 1124 | Interplay between Rab35 and Arf6 controls cargo recycling to coordinate cell adhesion and migration. **2013**, 126, 722-31 | 87 |

| 1123 | Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas. **2012**, 14, 1393-403 | 31 |

| 1122 | A fast and accurate SNP detection algorithm for next-generation sequencing data. **2012**, 3, 1258 | 34 |

| 1121 | Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. **2012**, 104, 1503-13 | 191 |

| 1120 | Reviewing the somatic genetics of melanoma: from current to future analytical approaches. **2012**, 25, 144-54 | 44 |

| 1119 | Delving into somatic variation in sporadic melanoma. **2012**, 25, 155-70 | 33 |

| 1118 | Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma. **2012**, 72, 4856-68 | 49 |

| 1117 | Synergistic effect of different levels of genomic data for cancer clinical outcome prediction. **2012**, 45, 1191-8 | 73 |

| 1116 | Stem Cells and Cancer Stem Cells: New Insights. **2012**, 17-31 | |

| 1115 | An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21.3 in glioblastoma. **2012**, 118, 232-40 | 33 |

| 1114 | Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models. **2012**, 30, 2161-72 | 8 |

| 1113 | Regulation of mRNA expression in breast cancer - a cis-tematic trans-action. **2012**, 14, 322 | 1 |

| 1112 | Assessing telomeric DNA content in pediatric cancers using whole-genome sequencing data. **2012**, 13, R113 | 28 |

1111   Unique biology of gliomas: challenges and opportunities. **2012**, 35, 546-56   54

1110   Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. **2012**, 22, 2120-9   178

1109   Bioinformatics for cancer immunology and immunotherapy. **2012**, 61, 1885-903   32

1108   Laminin alpha 2 enables glioblastoma stem cell growth. **2012**, 72, 766-78   117

1107   Issues in Omics Data Integration for Gene Set Analysis and Aberrant Pathway Identification. **2012**, 73, 528-534

1106   Multiple Response Regression for Gaussian Mixture Models with Known Labels. **2012**, 5, 493   2

1105   An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. **2012**, 23, 1443-9   32

1104   A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. **2012**, 110, 245-50   14

1103   Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. **2012**, 110, 195-203   49

1102   P2X7 receptor activation leads to increased cell death in a radiosensitive human glioma cell line. **2012**, 8, 729-39   37

1101   Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. **2012**, 22, 359-72   148

1100   Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. **2012**, 22, 425-37   1243

1099   The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. **2012**, 22, 765-80   153

1098   Anticancer activity of the cholesterol exporter ABCA1 gene. **2012**, 2, 580-90   122

1097   Glioblastoma heterogeneity and more accurate representation in research models. **2012**, 78, 594-6   4

1096   Terapie molecolari mirate e antiangiogeniche nel trattamento dei glioblastomi. **2012**, 12, 1-14

1095   IDH mutations in human glioma. **2012**, 23, 471-80   42

1094   Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases. **2012**, 5, 305-12   12

| 1093 | EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells. **2012**, 5, 379-92 | 29 |

| 1092 | Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. **2012**, 14, 420-8 | 103 |

| 1091 | Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma. **2012**, 8, 605 | 73 |

| 1090 | Recent developments on immunotherapy for brain cancer. **2012**, 17, 181-202 | 50 |

| 1089 | Nimotuzumab treatment of malignant gliomas. **2012**, 12, 1649-59 | 44 |

| 1088 | O6-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme. **2012**, 11, 2440-50 | 15 |

| 1087 | SAMNet: a network-based approach to integrate multi-dimensional high throughput datasets. **2012**, 4, 1415-27 | 19 |

| 1086 | Identifying mutated core modules in glioblastoma by integrative network analysis. **2012**, | |

| 1085 | Multiscale integration of -omic, imaging, and clinical data in biomedical informatics. **2012**, 5, 74-87 | 35 |

| 1084 | Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. **2012**, 19, 1353-61 | 79 |

| 1083 | Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. **2012**, 51, 1464-75 | 50 |

| 1082 | A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. **2012**, 61, 673-84 | 476 |

| 1081 | Genome sequencing identifies a basis for everolimus sensitivity. **2012**, 338, 221 | 546 |

| 1080 | Cortical and subventricular zone glioblastoma-derived stem-like cells display different molecular profiles and differential in vitro and in vivo properties. **2012**, 19 Suppl 3, S608-19 | 24 |

| 1079 | Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. **2012**, 39, 23-34 | 27 |

| 1078 | Comparative genomic and proteomic analysis of high grade glioma primary cultures and matched tumor in situ. **2012**, 318, 2245-56 | 4 |

| 1077 | Relax with CouchDB--into the non-relational DBMS era of bioinformatics. **2012**, 100, 1-7 | 24 |

| 1076 | Perspectives on personalized cancer care. **2012**, 30, 121-5 | |

1075   IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. **2012**, 18, 2490-501   108

1074   Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy. **2012**, 5, 173-86   99

1073   LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions. **2012**, 11, M111.013565   65

1072   PDGF-B-mediated downregulation of miR-21: new insights into PDGF signaling in glioblastoma. **2012**, 21, 5118-30   22

1071   Cadherin-11, a marker of the mesenchymal phenotype, regulates glioblastoma cell migration and survival in vivo. **2012**, 10, 293-304   50

1070   Cancer biomarkers: selecting the right drug for the right patient. **2012**, 11, 201-14   202

1069   Interfaces to PeptideAtlas: a case study of standard data access systems. **2012**, 13, 615-26   1

1068   What are we learning from the cancer genome?. **2012**, 9, 621-30   43

1067   Comparative analysis of somatic copy-number alterations across different human cancer types reveals two distinct classes of breakpoint hotspots. **2012**, 21, 4957-65   12

1066   STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. **2012**, 26, 1459-72   80

1065   Intratumor heterogeneity: evolution through space and time. **2012**, 72, 4875-82   628

1064   Endothelial Wnt/ß-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. **2012**, 209, 1611-27   101

1063   Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. **2012**, 109, 12722-7   30

1062   Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. **2012**, 12, 635-42   88

1061   Passenger deletions generate therapeutic vulnerabilities in cancer. *Nature*, **2012**, 488, 337-42   50.4   224

1060   Full-genome dissection of an epidemic of severe invasive disease caused by a hypervirulent, recently emerged clone of group A Streptococcus. **2012**, 180, 1522-34   63

1059   Amplification of the STOML3, FREM2, and LHFP genes is associated with mesenchymal differentiation in gliosarcoma. **2012**, 180, 1816-23   21

1058   The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. **2012**, 180, 2108-19   157

1057	Nature versus nurture in glioblastoma: microenvironment and genetics can both drive mesenchymal transcriptional signature. **2012**, 180, 1768-71	4
1056	A population approach to precision medicine. **2012**, 42, 639-45	100
1055	Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. **2012**, 16, 161-70	20
1054	Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases. **2012**, 52, 205-13	28
1053	Genome-wide studies of the transcriptional regulation by p53. **2012**, 1819, 684-7	6
1052	Opposing roles of connexin43 in glioma progression. **2012**, 1818, 2058-67	82
1051	Domain-mediated protein interaction prediction: From genome to network. **2012**, 586, 2751-63	35
1050	Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity. **2012**, 44, 738-47	25
1049	Genetically engineered mouse models of diffuse gliomas. **2012**, 88, 72-9	18
1048	Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. **2012**, 205, 391-404	26
1047	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. **2012**, 148, 59-71	600
1046	Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85 regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain. **2012**, 24, 1950-4	26
1045	New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. **2012**, 48, 1176-84	137
1044	Screens, maps & networks: from genome sequences to personalized medicine. **2012**, 22, 36-44	14
1043	Genome sequencing and cancer. **2012**, 22, 245-50	56
1042	Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. **2012**, 506, 62-8	13
1041	Comparison of different normalization assumptions for analyses of DNA methylation data from the cancer genome. **2012**, 506, 36-42	13
1040	Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. **2012**, 11, 133-44	56

1021	Comprehensive molecular characterization of human colon and rectal cancer. *Nature*, **2012**, 487, 330-7	50.4	5640
1020	Comprehensive molecular portraits of human breast tumours. *Nature*, **2012**, 490, 61-70	50.4	8025
1019	Sensitization of glioma cells by X-linked inhibitor of apoptosis protein knockdown. **2012**, 83, 75-82		13
1018	Polymorphisms in the 5?-UTR of PTEN and other gene polymorphisms in normal Japanese individuals. **2012**, 46, 74-88		
1017	A catalogue of glioblastoma and brain MicroRNAs identified by deep sequencing. **2012**, 16, 690-9		40
1016	An Introduction to Personalized Medicine. **2012**, 121-142		2
1015	Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. **2012**, 14, 1153-62		56
1014	Multiple roles for the p85 isoform in the regulation and function of PI3K signalling and receptor trafficking. **2012**, 441, 23-37		70
1013	Glioblastoma multiforme: Molecular characterization and current treatment strategy (Review). **2012**, 3, 9-14		60
1012	Next generation sequencing: chemistry, technology and applications. **2014**, 336, 1-18		31
1011	7.10 Cell-Extracellular Matrix Mechanobiology in Cancer. **2012**, 142-167		
1010	Dynamin 2 mediates PDGFR SHP-2-promoted glioblastoma growth and invasion. **2012**, 31, 2691-702		56
1009	USP15 stabilizes TGF- receptor I and promotes oncogenesis through the activation of TGF- signaling in glioblastoma. **2012**, 18, 429-35		280
1008	The Pediatric Cancer Genome Project. **2012**, 44, 619-22		239
1007	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature*, **2012**, 482, 226-31	50.4	1655
1006	GSVD comparison of patient-matched normal and tumor aCGH profiles reveals global copy-number alterations predicting glioblastoma multiforme survival. **2012**, 7, e30098		29
1005	A simplified approach for the molecular classification of glioblastomas. **2012**, 7, e45475		47
1004	Genes, Respiration, Viruses, and Cancer. **2012**, 145-176		1

1003   Overview of primary brain tumors: pathologic classification, epidemiology, molecular biology, and prognostic markers. **2012**, 26, 715-32   22

1002   Genetic insight and therapeutic targets in squamous-cell lung cancer. **2012**, 31, 4811-4   24

1001   Molecular subgroups of medulloblastoma. **2012**, 12, 871-84   103

1000   The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase ?**2012**, 55, 8007-20   39

999   EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. **2012**, 10, 20-26

998   Loss of Rb cooperates with Ras to drive oncogenic growth in mammalian cells. **2012**, 22, 1765-73   7

997   MEF promotes stemness in the pathogenesis of gliomas. **2012**, 11, 836-44   27

996   Structural mutations in cancer: mechanistic and functional insights. **2012**, 28, 550-9   54

995   Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. **2012**, 59, 193-201   85

994   Molecular pathology. **2012**, 6, 177-81   8

993   Omics and therapy - a basis for precision medicine. **2012**, 6, 128-39   30

992   A survey of copy-number variation detection tools based on high-throughput sequencing data. **2012**, Chapter 7, Unit7.19   18

991   Biomarker Discovery in Central Nervous System Neoplasms: Past, Present and Future. **2012**, 107-119

990   In vivo models of primary brain tumors: pitfalls and perspectives. **2012**, 14, 979-93   169

989   [Personalized therapeutic targeting by exome analysis]. **2012**, 32, S44-5

988   Considerations on Dealing with Tissues and Cell Samples (Include Tissue Banking). **2012**, 21-31

987   Early patient stratification and predictive biomarkers in drug discovery and development: a case study of ulcerative colitis anti-TNF therapy. **2012**, 736, 645-53   18

986   Malignancies of the spinal cord. **2012**, 760, 101-13   7

985	Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. **2012**, 7, e44372		35
984	Biomarkers classification and therapeutic decision-making for malignant gliomas. **2012**, 13, 417-36		22
983	RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas. **2012**, 14, 526-34		17
982	Netrin-4 promotes glioblastoma cell proliferation through integrin ⍰4 signaling. **2012**, 14, 219-27		32
981	Absolute quantification of somatic DNA alterations in human cancer. **2012**, 30, 413-21		1229
980	Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. **2012**, 31, 3039-50		59
979	Fastbreak: a tool for analysis and visualization of structural variations in genomic data. **2012**, 2012, 15		4
978	Neurofibromatosis Type 1. **2012**,		16
977	Comprehensive genomic characterization of squamous cell lung cancers. *Nature*, **2012**, 489, 519-25	50.4	2820
976	. **2012**, 29, 89-97		1
975	Glioblastoma--a moving target. **2012**, 117, 251-6		37
974	Applied Computational Genomics. **2012**,		
973	Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. **2012**, 31, 446-57		153
972	Glioma. **2012**,		2
971	Identification of markers associated with global changes in DNA methylation regulation in cancers. **2012**, 13 Suppl 13, S7		11
970	Model averaging strategies for structure learning in Bayesian networks with limited data. **2012**, 13 Suppl 13, S10		5
969	Simple binary segmentation frameworks for identifying variation in DNA copy number. **2012**, 13, 277		1
968	Combing the hairball with BioFabric: a new approach for visualization of large networks. **2012**, 13, 275		25

949	Cancer association study of aminoacyl-tRNA synthetase signaling network in glioblastoma. **2012**, 7, e40960	19
948	Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. **2012**, 7, e41036	128
947	A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature. **2012**, 7, e41522	70
946	Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. **2012**, 7, e43339	106
945	Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies. **2012**, 7, e43468	40
944	Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets. **2012**, 7, e45894	15
943	Amplified and homozygously deleted genes in glioblastoma: impact on gene expression levels. **2012**, 7, e46088	28
942	Predicting the functional effect of amino acid substitutions and indels. **2012**, 7, e46688	1840
941	Combined drug action of 2-phenylimidazo[2,1-b]benzothiazole derivatives on cancer cells according to their oncogenic molecular signatures. **2012**, 7, e46738	8
940	Conditional astroglial Rictor overexpression induces malignant glioma in mice. **2012**, 7, e47741	39
939	EGFR gene variants are associated with specific somatic aberrations in glioma. **2012**, 7, e47929	10
938	High quality genomic copy number data from archival formalin-fixed paraffin-embedded leiomyosarcoma: optimisation of universal linkage system labelling. **2012**, 7, e50415	18
937	Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer. **2012**, 7, e51719	12
936	Multi-analyte network markers for tumor prognosis. **2012**, 7, e52973	18
935	Histopathology of brain tumors. **2012**, 138-187	
934	Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas. **2011**, 10, 185-93	28
933	MicroRNAs in Human Malignant Gliomas. **2012**, 2012, 732874	23
932	The molecular profile of luminal B breast cancer. **2012**, 6, 289-97	116

931   Perspectives of Long Non-Coding RNAs in Cancer Diagnostics. **2012**, 3, 32   119

930   Leveraging ethnic group incidence variation to investigate genetic susceptibility to glioma: a novel candidate SNP approach. **2012**, 3, 203   11

929   EGFR and Tumor Suppressor Function in Brain Cancer Development. **2012**, 217-225

928   Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. **2012**, 50, 301-21   66

927   DNAmethylation profiling using Illumina BeadArray platform. 235-248   1

926   Toward prediction of immune mechanisms and design of immunotherapies in melanoma. **2012**, 40, 279-94   8

925   PIK3R1 (phosphoinositide-3-kinase, regulatory subunit 1 (alpha)). **2012**,

924   Neurogenetics and the molecular biology of human brain tumors. **2012**, 83-101

923   Genome-scale DNA methylation analyses of cancer in children. 338-346

922   High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. **2012**, 3, 1124-36   122

921   Glioblastoma: biology, genetics, and behavior. **2012**, 102-7   8

920   Full-Length Enrich c-DNA Libraries-Clear Cell-Renal Cell Carcinoma. **2012**, 2012, 680796   3

919   Molecular biomarkers of glioblastoma: current targets and clinical implications. **2012**, 63   4

918   Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. **2012**, 3, 709-22   439

917   REST regulates oncogenic properties of glioblastoma stem cells. **2012**, 30, 405-14   56

916   Mechanistic modeling to investigate signaling by oncogenic Ras mutants. **2012**, 4, 117-27   4

915   Reverse-engineering human regulatory networks. **2012**, 4, 311-25   42

914   Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins. **2012**, 12, 1093-110   126

913	Rai is a new regulator of neural progenitor migration and glioblastoma invasion. **2012**, 30, 817-32	28
912	Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. **2012**, 30, 1064-75	53
911	Numb regulates glioma stem cell fate and growth by altering epidermal growth factor receptor and Skp1-Cullin-F-box ubiquitin ligase activity. **2012**, 30, 1313-26	44
910	MAPK pathway activation in pilocytic astrocytoma. **2012**, 69, 1799-811	152
909	Drug discovery: Cell lines battle cancer. *Nature*, **2012**, 483, 544-5	50.4 73
908	Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. **2012**, 31, 1884-95	150
907	Translating cancer 'omics' to improved outcomes. **2012**, 22, 188-95	84
906	Cancer genomics: technology, discovery, and translation. **2012**, 30, 647-60	134
905	Detectable clonal mosaicism and its relationship to aging and cancer. **2012**, 44, 651-8	409
904	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature*, **2012**, 483, 479-83	50.4 1373
903	The cellular origin for malignant glioma and prospects for clinical advancements. **2012**, 12, 383-94	113
902	Malignant glioma: lessons from genomics, mouse models, and stem cells. **2012**, 149, 36-47	416
901	Genetics and epigenetics of the skin meet deep sequence. **2012**, 132, 923-32	11
900	Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. **2012**, 72, 1614-20	90
899	The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. **2012**, 16 Suppl 2, S17-27	472
898	A landscape of driver mutations in melanoma. **2012**, 150, 251-63	1799
897	Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. **2012**, 18, 184-95	127
896	Transforming fusions of FGFR and TACC genes in human glioblastoma. **2012**, 337, 1231-5	567

895 | The MET oncogene is a functional marker of a glioblastoma stem cell subtype. **2012**, 72, 4537-50 | 104

894 | Molecular biology of glioma. **2012**, 746, 2-11 | 50

893 | Emerging insights into the molecular and cellular basis of glioblastoma. **2012**, 26, 756-84 | 388

892 | The influence of race and ethnicity on the biology of cancer. **2012**, 12, 648-53 | 37

891 | An emerging toolkit for targeted cancer therapies. **2012**, 22, 177-82 | 18

890 | PTBP1-dependent regulation of USP5 alternative RNA splicing plays a role in glioblastoma tumorigenesis. **2012**, 51, 895-906 | 52

889 | De novo discovery of mutated driver pathways in cancer. **2012**, 22, 375-85 | 290

888 | Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters. **2012**, 8, 549-58 | 16

887 | Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. *Nature*, **2012**, 486, 80-4 | 50.4 | 258

886 | Molecular signatures from omics data: from chaos to consensus. **2012**, 7, 946-57 | 75

885 | Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-⊞IL-17+ polyfunctional T cells that mediate rejection of murine tumors. **2012**, 72, 581-91 | 77

884 | Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. **2012**, 14, 132-44 | 165

883 | Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. **2012**, 30, 48-56 | 173

882 | Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. **2012**, 18, 1515-23 | 37

881 | Oncogenomics methods and resources. **2012**, 2012, | 7

880 | Paediatric and adult malignant glioma: close relatives or distant cousins?. **2012**, 9, 400-13 | 131

879 | From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. **2012**, 12, 572-8 | 66

878 | De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. **2012**, 44, 934-40 | 521

877   Targeting DNA repair and the cell cycle in glioblastoma. **2012**, 107, 463-77   28

876   Recent advances in the molecular understanding of glioblastoma. **2012**, 108, 11-27   269

875   Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. **2012**, 108, 499-506   36

874   Trans-membrane peptide therapy for malignant glioma by use of a peptide derived from the MDM2 binding site of p53. **2012**, 109, 7-14   9

873   Rho GTPases in primary brain tumor malignancy and invasion. **2012**, 108, 333-9   38

872   Exploring the cancer genome in the era of next-generation sequencing. **2012**, 6, 48-55   20

871   Clinical implications of molecular neuropathology and biomarkers for malignant glioma. **2012**, 12, 302-7   20

870   Anaplastic glioma. **2012**, 14, 381-90   13

869   Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. **2012**, 69, 1507-18   50

868   The "go or grow" potential of gliomas is linked to the neuropeptide processing enzyme carboxypeptidase E and mediated by metabolic stress. **2012**, 124, 83-97   56

867   A review of the role of stem cells in the development and treatment of glioma. **2012**, 154, 951-69; discussion 969   11

866   Advances in biotechnology and linking outputs to variation in complex traits: Plant and Animal Genome meeting January 2012. **2012**, 12, 1-9   5

865   Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents. **2012**, 64, 605-13   76

864   Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. **2012**, 271, 111-21   147

863   Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. **2012**, 21, 11-24   112

862   Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. **2012**, 21, 601-613   141

861   Converging miRNA functions in diverse brain disorders: a case for miR-124 and miR-126. **2012**, 235, 427-35   75

860   My path toward DNA repair. **2012**, 11, 606-15   1

859	Contribution of microRNAs to radio- and chemoresistance of brain tumors and their therapeutic potential. **2012**, 684, 8-18	44
858	Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma. **2012**, 16, 545-54	21
857	Evaluating the genomic and sequence integrity of human ES cell lines; comparison to normal genomes. **2012**, 8, 154-64	20
856	Simultaneous Multiple Response Regression and Inverse Covariance Matrix Estimation via Penalized Gaussian Maximum Likelihood. **2012**, 111, 241-255	32
855	Direct mutation analysis by high-throughput sequencing: from germline to low-abundant, somatic variants. **2012**, 729, 1-15	67
854	Evolution of the cancer genome. **2012**, 28, 155-63	98
853	Review: insights gained from modelling high-grade glioma in the mouse. **2012**, 38, 254-70	15
852	Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. **2012**, 38, 271-91	86
851	StratomeX: Visual Analysis of Large-Scale Heterogeneous Genomics Data for Cancer Subtype Characterization. **2012**, 31, 1175-1184	59
850	RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. **2012**, 12, 22	149
849	MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. **2012**, 10, 36	70
848	Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies. **2012**, 6, 3	20
847	Insights into the pathogenesis of axial spondyloarthropathy from network and pathway analysis. **2012**, 6 Suppl 1, S4	8
846	Integration of global spectral karyotyping, CGH arrays, and expression arrays reveals important genes in the pathogenesis of glioblastoma multiforme. **2012**, 19, 2367-79	7
845	The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. **2012**, 4, 38-51	69
844	DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines. **2012**, 130, 267-77	31
843	Authors' reply to Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. **2012**, 130, 2217-2218	0
842	Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. **2012**, 130, 2215-7; author reply 2217-8	4

841   The promoter hypermethylation status of GATA6, MGMT, and FHIT in glioblastoma. **2012**, 32, 237-44   21

840   Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. **2012**, 107, 1-12   42

839   Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting. **2012**, 123, 369-80   31

838   Next generation sequencing and a new era of medicine. **2013**, 62, 920-32   19

837   Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. **2013**, 8, 65   69

836   Role of metabotropic glutamate receptor 5 signaling and homer in oxygen glucose deprivation-mediated astrocyte apoptosis. **2013**, 6, 9   27

835   Integrated analysis of recurrent properties of cancer genes to identify novel drivers. **2013**, 14, R52   29

834   Patchwork: allele-specific copy number analysis of whole-genome sequenced tumor tissue. **2013**, 14, R24   51

833   Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma. **2013**, 28, 355-66   15

832   KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. **2013**, 154, 541-55   155

831   Bio and health informatics meets cloud : BioVLab as an example. **2013**, 1, 6   13

830   Cancer Genomics. **2013**,   4

829   OpenSPIM: an open-access light-sheet microscopy platform. **2013**, 10, 598-9   215

828   Cilia and Nervous System Development and Function. **2013**,   4

827   Invasion as target for therapy of glioblastoma multiforme. **2013**, 1836, 236-44   63

826   Primary Central Nervous System Tumors in the Aging Population. **2013**, 2, 182-187

825   The integrated landscape of driver genomic alterations in glioblastoma. **2013**, 45, 1141-9   400

824   Knockdown of NOB1 expression by RNAi inhibits cellular proliferation and migration in human gliomas. **2013**, 528, 146-53   13

805	LGR5 is a proneural factor and is regulated by OLIG2 in glioma stem-like cells. **2013**, 33, 851-65	15
804	Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. **2013**, 18, 1447-68	107
803	Metabolic modulation of epigenetics in gliomas. **2013**, 23, 217-21	37
802	PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. **2013**, 23, 565-73	71
801	Molecular neuro-oncology in clinical practice: a new horizon. **2013**, 14, e370-9	149
800	Emerging Concepts in Neuro-Oncology. **2013**,	
799	Next Generation Sequencing in Cancer Research. **2013**,	4
798	Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. **2013**, 62, 1499-509	169
797	A comparative study of primary and recurrent human glioblastoma multiforme using the small animal imaging and molecular expressive profiles. **2013**, 15, 262-72	8
796	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. **2013**, 126, 443-51	239
795	In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing. **2013**, 125, 671-81	62
794	Loss of p53 cooperates with K-ras activation to induce glioma formation in a region-independent manner. **2013**, 61, 1862-72	15
793	Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. **2013**, 16, 1373-82	306
792	Role of phosphatidylinositol 3,4,5-trisphosphate in cell signaling. **2013**, 991, 105-39	25
791	The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. **2013**, 24, 365-78	102
790	Lipid-mediated Protein Signaling. **2013**,	6
789	The genomic landscape of oesophagogastric junctional adenocarcinoma. **2013**, 231, 301-10	31
788	Multifunctional protein APPL2 contributes to survival of human glioma cells. **2013**, 7, 67-84	13

769	The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. **2013**, 19, 5722-32	35
768	OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. **2013**, 29, 2238-44	276
767	Molecular pathways and potential therapeutic targets in glioblastoma multiforme. **2013**, 13, 1307-18	2
766	Analysis of microRNA-target interactions across diverse cancer types. **2013**, 20, 1325-32	153
765	The somatic genomic landscape of glioblastoma. **2013**, 155, 462-77	2900
764	Micro and Nano Flow Systems for Bioanalysis. **2013**,	2
763	Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. **2013**, 15, 829-39	74
762	Introduction: sifting through the characterization of hematologic malignancies. **2013**, 50, 284-5	
761	De-repression of PDGFRβtranscription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. **2013**, 3, 534-47	90
760	ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms. **2013**, 20, 200-8	38
759	Data Mining for Systems Biology. **2013**,	1
758	Mutational landscape and significance across 12 major cancer types. *Nature*, **2013**, 502, 333-339	50.4 2803
757	Experimental validation of 5 in-silico predicted glioma biomarkers. **2013**, 15, 1625-34	24
756	Tumor Phylogenetics in the NGS Era: Strategies, Challenges, and Future Prospects. **2013**, 335-357	
755	IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. **2013**, 9, 1923-35	46
754	Metabolic mechanisms of epigenetic regulation. **2013**, 8, 2607-21	48
753	Identification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data. **2013**, 7 Suppl 2, S4	28
752	Emerging roles of competing endogenous RNAs in cancer: insights from the regulation of PTEN. **2013**, 33, 3976-82	65

751	Bioinformatics for Diagnosis, Prognosis and Treatment of Complex Diseases. **2013**,	
750	The Cancer Genome Atlas Pan-Cancer analysis project. **2013**, 45, 1113-20	3933
749	Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. **2013**, 19, 4951-60	134
748	A simple consensus approach improves somatic mutation prediction accuracy. **2013**, 5, 90	29
747	cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome. **2013**, 115, 249-59	25
746	Bayesian methods for expression-based integration of various types of genomics data. **2013**, 2013, 13	17
745	Identification of genetic markers with synergistic survival effect in cancer. **2013**, 7 Suppl 1, S2	1
744	Reconstructing and characterizing focal amplifications in cancer using AmpliconArchitect.	0
743	Dynamics of microRNA expression during mouse prenatal development.	1
742	Characterizing and comparing missense variants in monogenic disease and in cancer.	1
741	Case Studies: Molecular Pathology Perspective and Impact on Oncologic Patients Management. **2019**, 191-216	
740	The role of the deficient DNA mismatch repair system as a factor of sensitivity to targeted therapy for glioblastoma multiforme. **2019**, 8, 379	
739	Bioinformatics in Skin Cancer: A System Biology Approach to Understanding the Molecular Mechanisms and Its Regulations. **2019**, 101-111	
738	Quantitative Proteomics Reveals Global Reduction of Endocytic Machinery Components in Gliomas.	
737	RBL1 (p107) functions as tumor suppressor in glioblastoma and small-cell pancreatic neuroendocrine carcinoma.	1
736	Combining the "Sibling Technologies" of Laser Capture Microdissection and Reverse Phase Protein Microarrays. **2019**, 1188, 95-111	0
735	Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens.	
734	Uncovering the subtype-specific temporal order of cancer pathway dysregulation.	

| 733 | Unexpectedly High Subclonal Mutational Diversity in Human Colorectal Cancer and Its Significance. | 1 |

| 732 | A Cre-amplifier to generate and detect genetic mosaicsin vivo. | 0 |

| 731 | Tumor Sequencing: Enabling Personalized Targeted Treatments with Informatics. **2020**, 161-174 | |

| 730 | RADIO-iBAG: RADIOMICS-BASED INTEGRATIVE BAYESIAN ANALYSIS OF MULTIPLATFORM GENOMIC DATA. **2019**, 13, 1957-1988 | 3 |

| 729 | Found in Transcription: Gene fusions arise through defects in RNA processing in the absence of chromosomal rearrangements. | |

| 728 | Implications ofMGMTpromoter methylation and its downstreamhMSH2mRNA in primary malignant glioma. | |

| 727 | Imaging Genomics. **2020**, 223-239 | |

| 726 | The Role of Next Generation Sequencing in Diagnosis of Brain Tumors: A Review Study. **2019**, 7, | 0 |

| 725 | The efficacy of DNA MMR enzyme immunohistochemistry as a screening test for hypermutated gliomas. | |

| 724 | The Topology of Mutated Driver Pathways. | 0 |

| 723 | eVIP2: Expression-based variant impact phenotyping to predict the function of gene variants. | 0 |

| 722 | Chemotherapy and Future Developments. **2020**, 29-37 | |

| 721 | ASCL1 regulates neurodevelopmental transcription factors and cell cycle genes in glioblastoma. | |

| 720 | Premalignant Nf1, Trp53-null Oligodendrocyte Precursor Cells Become Stalled in a Heterogeneous State of Replication Stress Before Gliomagenesis. | 2 |

| 719 | Punctuated Aneuploidization of the Budding Yeast Genome. | 0 |

| 718 | Uncertainty Quantification in Radiogenomics: EGFR Amplification in Glioblastoma. | |

| 717 | Brain Tumor IDH, 1p/19q, and MGMT Molecular Classification Using MRI-based Deep Learning: Effect of Motion and Motion Correction. | 2 |

| 716 | Diagnostic Evidence GAuge of Single cells (DEGAS): A flexible deep-transfer learning framework for prioritizing cells in relation to disease. | 1 |

697	GARD is a pan-cancer predictor of radiation therapy benefit.	
696	An evaluation of promoter methylation within the methylation subclasses of glioblastoma. **2020**, 2, vdaa117	1
695	Mapping chromatin accessibility and active regulatory elements reveals new pathological mechanisms in human gliomas.	0
694	Identification of ZG16B as a prognostic biomarker in breast cancer. **2021**, 16, 1-13	11
693	PDAC Subtypes/Stratification. **2020**, 117-128	0
692	Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma. **2020**, 2, vdaa151	0
691	Applications of Quantitative Perfusion and Permeability in the Brain. **2020**, 1, 369-403	
690	Glioblastoma. **2020**, 173-182	
689	Genetic, Cellular, and Connectomic Characterization of the Adult Human Brain Regions Commonly Plagued by Glioma.	1
688	The irradiated brain microenvironment supports glioma stemness and survival via astrocyte-derived Transglutaminase 2.	
687	MONET: Multi-omic patient module detection by omic selection.	0
686	LZTR1 inactivation promotes MAPK/ ERK pathway activation in glioblastoma by stabilizing oncoprotein RIT1.	1
685	Functional variations of NFKB1 and NFKB1A in inflammatory disorders and their implication for therapeutic approaches. **2020**, 14, 47-57	0
684	Identifying the spatial and temporal dynamics of molecularly-distinct glioblastoma sub-populations.	
683	Glioblastoma: a molecular genetic portrait and modern therapeutic strategies for drug treatment. **2021**, 8, 60-76	
682	Anatomical structures, cell types and biomarkers of the Human Reference Atlas. **2021**, 23, 1117-1128	6
681	Single-Cell Transcriptomic Analysis Revealed a Critical Role of SPP1/CD44-Mediated Crosstalk Between Macrophages and Cancer Cells in Glioma. **2021**, 9, 779319	4
680	Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients. **2021**, 41,	0

679   Novel Ion Channel Targets and Drug Delivery Tools for Controlling Glioblastoma Cell Invasiveness. **2021**, 22,   3

678   Integrative analysis of DNA methylation and gene expression profiles to identify biomarkers of glioblastoma. **2021**, 258-259, 135-150   0

677   Dynamic multi-OMICs of glioblastoma reveal sensitivity to neddylation inhibition dependent on nuclear PTEN and DNA replication pathways: Nuclear PTEN mediates MLN4924 sensitivity in GBM.

676   Cancer genomic medicine in Japan. **2020**, 96, 316-321   5

675   Multi-Fractal Analysis for Feature Extraction from DNA Sequences. 100-118

674   Prediction of Epigenetic Target Sites by Using Genomic DNA Sequence. 498-512

673   Dynamical Analysis of Drug Efficacy and Mechanism of Action Using GFP Reporters. 316-353

672   Glioblastoma molecular and histological heterogeneity. **2020**, 9, 5-11

671   Consensus clustering applied to multi-omic disease subtyping.

670   Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells. **2020**, 11, 3933-3942

669   LncRNA IDH1-AS1 suppresses cell proliferation and tumor growth in glioma. **2020**, 98, 556-564   1

668   Identifying Cross-Cancer Similar Patients via a Semi-Supervised Deep Clustering Approach.

667   A Scalable, Open-Source Implementation of a Large-Scale Mechanistic Model for Single Cell Proliferation and Death Signaling.

666   The white matter is a pro-differentiative microenvironment for glioblastoma.

665   STATegra: Multi-omics data integration - A conceptual scheme and a bioinformatics pipeline.

664   Correlation of genetic alterations by whole-exome sequencing with clinical outcomes of glioblastoma patients from the Lebanese population. **2020**, 15, e0242793

663   FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma. **2021**, 8, 209-221   1

662   Impact of the next generation DNA sequencers. **2009**, 2, 193-202   6

661   BeadDataPackR: A Tool to Facilitate the Sharing of Raw Data from Illumina BeadArray Studies. **2010**, 9, 217-27   1

660   XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. **2010**, 13, 112-21   44

659   Therapy-, gender- and race-specific microRNA markers, target genes and networks related to glioblastoma recurrence and survival. **2011**, 8, 173-83   30

658   Integrating genome and functional genomics data to reveal perturbed signaling pathways in ovarian cancers. **2012**, 2012, 72-8   5

657   Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions. **2012**, 26, 487-500   4

656   Identifying master regulators of cancer and their downstream targets by integrating genomic and epigenomic features. **2013**, 123-34   12

655   Role of SOX family of transcription factors in central nervous system tumors. **2014**, 4, 312-24   41

654   Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. **2014**, 4, 608-28   19

653   A mathematical model for short-term vs. long-term survival in patients with glioma. **2014**, 4, 862-73   8

652   Aging-related gene signature regulated by Nlrp3 predicts glioma progression. **2015**, 5, 442-9   24

651   MicroRNA-19a promotes glioma cell growth by repressing LRIG1. **2014**, 7, 5067-74   3

650   Cabozantinib Loaded DSPE-PEG Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation. **2015**, 1,   3

649   Downregulation of ring-finger protein 43 in glioma associates with poor prognosis. **2015**, 8, 490-6   5

648   Motivating the additional use of external validity: examining transportability in a model of glioblastoma multiforme. **2014**, 2014, 1930-9   2

647   Prostaglandin transporter, SLCO2A1, mediates the invasion and apoptosis of lung cancer cells via PI3K/AKT/mTOR pathway. **2015**, 8, 9175-81   13

646   Joint Estimation of Multiple Precision Matrices with Common Structures. **2015**, 16, 1035-1062   15

645   The CDKN2A-CDKN2B rs4977756 polymorphism and glioma risk: a meta-analysis. **2015**, 8, 17480-8   4

644   Identifying the genes regulated by IDH1 via gene-chip in glioma cell U87. **2015**, 8, 18090-8   2

643   Impaired TGF-Induced growth inhibition contributes to the increased proliferation rate of neural stem cells harboring mutant p53. **2015**, 5, 3436-45   5

642   KNOWLEDGE-ASSISTED APPROACH TO IDENTIFY PATHWAYS WITH DIFFERENTIAL DEPENDENCIES. **2016**, 21, 33-44   7

641   High expression of WDR1 in primary glioblastoma is associated with poor prognosis. **2016**, 8, 1253-64   11

640   Assessment of epidermal growth factor receptor status in glioblastomas. **2013**, 1, 47-52

639   MiR-422a acts as a tumor suppressor in glioblastoma by targeting PIK3CA. **2016**, 6, 1695-707   14

638   The E3 ubiquitin ligase CHIP/miR-92b/PTEN regulatory network contributes to tumorigenesis of glioblastoma. **2017**, 7, 289-300   14

637   ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells. **2018**, 8, 792-809   15

636   Genomics of adult and pediatric solid tumors. **2018**, 8, 1356-1386   12

635   [Advances on Recognizing and Managing Tumor Heterogeneity]. **2018**, 21, 712-718   1

634   Simultaneous Clustering and Estimation of Heterogeneous Graphical Models. **2018**, 18,   3

633   MiR-28-5p promotes human glioblastoma cell growth through inactivation of FOXO1. **2019**, 12, 2972-2980   3

632   Identification of three glioblastoma subtypes and a six-gene prognostic risk index based on the expression of growth factors and cytokines. **2020**, 12, 4669-4682   3

631   The association of a genetic variant in CDKN2A/B gene and the risk of colorectal cancer. **2020**, 19, 1316-1321

630   Cancer and pulmonary hypertension: Learning lessons and real-life interplay. **2020**, 2020, e202010   1

629   CEBPG promotes esophageal squamous cell carcinoma progression by enhancing PI3K-AKT signaling. **2020**, 10, 3328-3344   4

628   Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors. **2020**, 10, 3765-3783   2

627   Gene Expression Subtyping Reveals Immune alterations:TCGA Database for Prognosis in Ovarian Serous Cystadenocarcinoma. **2021**, 8, 619027   2

626   Lesion covariance networks reveal proposed origins and pathways of diffuse gliomas.. **2021**, 3, fcab289   1

625	Immunopharmaco-genomics: future of clinical medicine. **2022**, 347-384	
624	Alterations in the RB Pathway With Inactivation of RB1 Characterize Glioblastomas With a Primitive Neuronal Component. **2021**,	0
623	Multiple Survival Outcome Prediction of Glioblastoma Patients Based on Multiparametric MRI.. **2021**, 11, 778627	0
622	The F-box protein, FBXO7 is required to maintain chromosome stability in humans. **2021**,	1
621	Smurf1 silencing restores PTEN expression that ameliorates progression of human glioblastoma and sensitizes tumor cells to mTORC1/C2 inhibitor Torin1.. **2021**, 24, 103528	0
620	A Syx-RhoA-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma.	
619	A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma.. **2021**, 10,	1
618	TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas.. **2022**,	1
617	Efficient Visualization of Whole Slide Images in Web-based Viewers for Digital Pathology.. **2021**,	
616	Topographic mapping of the glioblastoma proteome reveals a triple-axis model of intra-tumoral heterogeneity.. **2022**, 13, 116	1
615	Comprehensive omics analyses profile genesets related with tumor heterogeneity of multifocal glioblastomas and reveal LIF/CCL2 as biomarkers for mesenchymal subtype.. **2022**, 12, 459-473	1
614	Genetic Analysis Reveals the Prognostic Significance of the DNA Mismatch Repair Gene in Advanced Prostate Cancer.. **2022**, 14,	2
613	STAT3 Enhances Sensitivity of Glioblastoma to Drug-Induced Autophagy-Dependent Cell Death.. **2022**, 14,	3
612	Unravelling glioblastoma heterogeneity by means of single-cell RNA sequencing.. **2021**, 527, 66-79	3
611	A novel co-targeting strategy of EGFR/SEC61G for multi-modality fluorescence/MR/photoacoustic imaging of glioblastoma.. **2021**, 102509	0
610	The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attack.. **2021**, 181, 114082	2
609	Current insights on extracellular vesicle-mediated glioblastoma progression: Implications in drug resistance and epithelial-mesenchymal transition.. **2021**, 1866, 130065	1
608	Cancer and pulmonary hypertension: Learning lessons and real-life interplay. **2020**, 2020, e202010	1

607	Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells. **2021**,	4
606	NMNAT promotes glioma growth through regulating post-translational modifications of P53 to inhibit apoptosis.. **2021**, 10,	1
605	gcMECM: graph clustering of mutual exclusivity of cancer mutations.. **2021**, 22, 592	
604	Circular RNAs and glioblastoma multiforme: focus on molecular mechanisms.. **2022**, 20, 13	2
603	Intratumor morphologic and molecular genetic heterogeneity in astrocytomas of different grade of malignancy in the material from the first operation. **2022**, 20, 55-68	
602	Deep learning identified glioblastoma subtypes based on internal genomic expression ranks.. **2022**, 22, 86	0
601	The influence of the blood-brain barrier in the treatment of brain tumours.. **2022**,	2
600	Comparative assessment of genes driving cancer and somatic evolution in non-cancer tissues: an update of the Network of Cancer Genes (NCG) resource.. **2022**, 23, 35	0
599	Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma.. **2022**, 4, vdac002	0
598	CircCDK14 Promotes Tumor Progression and Resists Ferroptosis in Glioma by Regulating PDGFRA.. **2022**, 18, 841-857	0
597	CpG Island Methylator Phenotype-A Hope for the Future or a Road to Nowhere?. **2022**, 23,	3
596	A human DNA methylation atlas reveals principles of cell type-specific methylation and identifies thousands of cell type-specific regulatory elements.	0
595	The phosphatase and tensin homolog gene inserted between NP and P gene of recombinant New castle disease virus oncolytic effect test to glioblastoma cell and xenograft mouse model.. **2022**, 19, 21	0
594	High Dimensional Gaussian Graphical Regression Models with Covariates. 1-36	
593	Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.. **2022**, 23,	2
592	Dynamic Intercell Communication between Glioblastoma and Microenvironment through Extracellular Vesicles.. **2022**, 10,	0
591	Ceramide Composition in Exosomes for Characterization of Glioblastoma Stem-Like Cell Phenotypes.. **2021**, 11, 788100	0
590	Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer.. **2022**, 60, 100811	3

589 Necrotic reshaping of the glioma microenvironment drives disease progression.. **2022**, 143, 291   0

588 PAQR5 Expression Is Suppressed by TGFⱠ and Associated With a Poor Survival Outcome in Renal Clear Cell Carcinoma.. **2021**, 11, 827344   1

587 Spatially resolved single-cell deconvolution of bulk RNA-seq using Bulk2Space.

586 Single-cell RNA profiling identifies diverse cellular responses to EWSR1/FLI1 downregulation in Ewing sarcoma cells.. **2022**, 45, 19   3

585 Exome sequencing of glioblastoma-derived cancer stem cells reveals rare clinically relevant frameshift deletion in MLLT1 gene.. **2022**, 22, 9

584 Extracellular vesicles derived from glioblastoma promote proliferation and migration of neural progenitor cells via PI3K-Akt pathway.. **2022**, 20, 7   2

583 Genomic Landscape of TCR Alpha-Beta and TCR Gamma-Delta T-Large Granular Lymphocyte Leukemia.. **2022**,   1

582 The RASopathies: Biology, genetics and therapeutic options.. **2022**, 153, 305-341   0

581 E2F and STAT3 provide transcriptional synergy for histone variant H2AZ activation to sustain glioblastoma chromatin accessibility and tumorigenicity.. **2022**,   3

580 Constructing a Cancer Patient-Specific Network Based on Second-Order Partial Correlations of Gene Expression and DNA Methylation.. **2022**, PP,

579 Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors.. **2022**, 14,   2

578 An oncogenic splice variant of PDGFRⱠin adult glioblastoma as a therapeutic target for selective CDK4/6 inhibitors.. **2022**, 12, 1275   1

577 CD44-Mediated Poor Prognosis in Glioma Is Associated With M2-Polarization of Tumor-Associated Macrophages and Immunosuppression.. **2021**, 8, 775194   1

576 Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide.. **2022**, 14,

575 Diagnostic Evidence GAuge of Single cells (DEGAS): a flexible deep transfer learning framework for prioritizing cells in relation to disease.. **2022**, 14, 11   0

574 EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma.. **2022**, 7, 33   3

573 Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture.. **2022**,   0

572 Parental histone deposition on the replicated strands promotes error-free DNA damage tolerance and regulates drug resistance.. **2022**,   2

553	NCAPG as a Novel Prognostic Biomarker in Glioma.. **2022**, 12, 831438	0
552	Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?. **2022**, 10, 854352	1
551	Pan-Cancer Transcriptomic Analysis Identifies PLK1 Crucial for the Tumorigenesis of Clear Cell Renal Cell Carcinoma.. **2022**, 15, 1099-1116	0
550	MUC16 mutation is associated with tumor grade, clinical features, and prognosis in glioma patients.	
549	Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.. **2022**,	1
548	Deciphering specific miRNAs in brain tumors: a 5-miRNA signature in glioblastoma.. **2022**, 297, 507	1
547	Feature screening for survival trait with application to TCGA high-dimensional genomic data.. **2022**, 10, e13098	
546	Cytochromes P450: Role in Carcinogenesis and Relevance to Cancers.. **2022**,	0
545	Modeling of Aryl Hydrocarbon Receptor Pathway Intrinsic Immunometabolic Role using Glioblastoma Stem Cells and Patient-Derived Organoids.	
544	Production and Stabilization of Specific Upregulated Long Noncoding RNA HOXD-AS2 in Glioblastomas Are Mediated by TFE3 and miR-661, Respectively.. **2022**, 23,	
543	PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.. **2022**,	0
542	Multi-omic integrated curvature study on pan-cancer genomic data.	0
541	MultiGATAE: A Novel Cancer Subtype Identification Method Based on Multi-Omics and Attention Mechanism.. **2022**, 13, 855629	0
540	The metabolomic landscape plays a critical role in glioma oncogenesis.. **2022**,	0
539	EviCor: Interactive Web Platform for Exploration of Molecular Features and Response to Anti-cancer Drugs. **2022**, 167528	1
538	LPPR5 Expression in Glioma Affects Growth, Vascular Architecture, and Sunitinib Resistance.. **2022**, 23,	1
537	Histone deacetylase 7: a signalling hub controlling development, inflammation, metabolism and disease.. **2022**,	0
536	miR-3189-targeted GLUT3 repression by HDAC2 knockdown inhibits glioblastoma tumorigenesis through regulating glucose metabolism and proliferation.. **2022**, 41, 87	2

535	Hypoxia-induced GLT8D1 promotes glioma stem cell maintenance by inhibiting CD133 degradation through N-linked glycosylation.. **2022**,		2
534	Nucleolar localization of the ErbB3 receptor as a new target in glioblastoma.. **2022**, 23, 13		0
533	Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas.. **2022**, 10, 32		0
532	Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance.. **2022**, 12, 852950		4
531	Enhancing Characteristic Gene Selection and Tumor Classification by the Robust Laplacian Supervised Discriminative Sparse PCA.. **2022**,		1
530	Single-Cell Molecular Characterization to Partition the Human Glioblastoma Tumor Microenvironment Genetic Background.. **2022**, 11,		0
529	USF1/CD90 signaling in maintaining glioblastoma stem cells and tumor-associated macrophages adhesion.. **2022**,		1
528	Delivering Glioblastoma a Kick-DGK Inhibition as a Promising Therapeutic Strategy for GBM.. **2022**, 14,		
527	Proteomic analysis reveals microvesicles containing NAMPT as mediators of radiation resistance in glioma.		
526	Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.. **2022**,		0
525	The Subventricular Zone in Glioblastoma: Genesis, Maintenance, and Modeling.. **2022**, 12, 790976		1
524	Anatomic position determines oncogenic specificity in melanoma.. *Nature*, **2022**,	50.4	3
523	PTBP1 is a Novel Poor Prognostic Factor for Glioma.. **2022**, 2022, 7590997		1
522	Molecular landscape of IDH-wildtype, H3-wildtype glioblastomas of adolescents and young adults (AYA).. **2022**,		
521	The ability to classify patients based on gene-expression data varies by algorithm and performance metric.. **2022**, 18, e1009926		0
520	Overexpression of prothymosin-alpha in glioma is associated with tumor aggressiveness and poor prognosis.. **2022**,		0
519	Practice guidelines for tumour testing in ovarian cancer.. **2022**,		1
518	Understanding nanomedicine treatment in an aggressive spontaneous brain cancer model at the stage of early blood brain barrier disruption.. **2022**, 283, 121416		0

517	Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.. **2022**, 12, 5827	1
516	MicroRNA 3928 Suppresses Glioblastoma through Downregulation of Several Oncogenes and Upregulation of p53.. **2022**, 23,	0
515	Recognition of a Novel Gene Signature for Human Glioblastoma.. **2022**, 23,	0
514	Weighted Gene Coexpression Network Analysis Identifies TBC1D10C as a New Prognostic Biomarker for Breast Cancer.. **2022**, 2022, 5259187	
513	Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma.. **2022**, 14,	0
512	Patient-Derived Xenotransplant of CNS Neoplasms in Zebrafish: A Systematic Review.. **2022**, 11,	
511	Driver Gene Detection through Bayesian Network Integration of Mutation and Expression Profiles.. **2022**,	
510	Bayesian networks elucidate complex genomic landscapes in cancer.. **2022**, 5, 306	1
509	Surgical treatment of brain gliomas. **2021**, 15, 213-217	
508	Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma. **2021**, 22,	4
507	Transcriptional Regulation of Amino Acid Transport in Glioblastoma Multiforme.. **2021**, 13,	0
506	Live-Cell Synchrotron-Based FTIR Evaluation of Metabolic Compounds in Brain Glioblastoma Cell Lines after Riluzole Treatment.. **2021**,	1
505	ADD3 Deletion in Glioblastoma Predicts Disease Status and Survival.. **2021**, 11, 717793	
504	FOXO3 regulates a common genomic program in aging and glioblastoma stem cells. **2021**, 2, 137-159	0
503	Tissue remodeling and cell signaling underpin changes in tumor microenvironment heterogeneity in glioma oncogenesis.	
502	Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma.. **2021**,	0
501	Artificial intelligence in clinical research of cancers.. **2021**,	2
500	Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer.. **2021**, 12, 689076	5

499	ALDH1A3 Segregated Expression and Nucleus-Associated Proteasomal Degradation Are Common Traits of Glioblastoma Stem Cells.. **2021**, 10,	1
498	Conditional prediction of consecutive tumor evolution using cancer progression models: What genotype comes next?. **2021**, 17, e1009055	0
497	Hippo Pathway in Regulating Drug Resistance of Glioblastoma.. **2021**, 22,	3
496	Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment.. **2021**, 10,	4
495	Patient-Oriented Perspective on Chemokine Receptor Expression and Function in Glioma.. **2021**, 14,	0
494	Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds. **2021**,	4
493	Comprehensive transcriptomic characterization reveals core genes and module associated with immunological changes via 1619 samples of brain glioma. **2021**, 12, 1140	2
492	Combining an Autophagy Inhibitor, MPT0L145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment. **2021**, 13,	1
491	PTEN inhibits AMPK to control collective migration.	
490	Integration of Diverse Transcriptomics Datasets using Random Forest to Predict Universal Functional Pathways in Tfr Cells.	
489	Systems Biology Approaches to Decipher the Underlying Molecular Mechanisms of Glioblastoma Multiforme.. **2021**, 22,	0
488	Growth factor independence underpins a paroxysmal, aggressive Wnt5a/EphA2 phenotype in glioblastoma stem cells, conducive to experimental combinatorial therapy.. **2022**, 41, 139	1
487	Development of Tissue-Agnostic Treatments for Patients with Cancer. **2022**, 6, 147-165	2
486	Galvanotactic Migration of Glioblastoma and Brain Metastases Cells.. **2022**, 12,	0
485	Emerging therapies for glioblastoma: current state and future directions.. **2022**, 41, 142	7
484	Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review).. **2022**, 60,	3
483	Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma.. **2022**,	0
482	Flap endonuclease 1 and DNA-PKcs synergistically participate in stabilizing replication fork to encounter replication stress in glioma cells.. **2022**, 41, 140	0

481	The Interplay of Microtubules with Mitochondria-ER Contact Sites (MERCs) in Glioblastoma.. **2022**, 12,	1
480	Identification of a key glioblastoma candidate gene, FUBP3, based on weighted gene co-expression network analysis.. **2022**, 22, 139	1
479	Regional Development of Glioblastoma: The Anatomical Conundrum of Cancer Biology and Its Surgical Implication.. **2022**, 11,	2
478	Immune Landscape in PTEN-Related Glioma Microenvironment: A Bioinformatic Analysis.. **2022**, 12,	1
477	High-throughput functional evaluation of human cancer-associated mutations using base editors.. **2022**,	0
476	General and special techniques in surgical pathology and cytopathology. 18-84	
475	Pancreatic cancer. 409-420	
474	Cancer pharmacogenomics: challenges, promises, and its application to cancer drug discovery. 499-517	
473	Image_1.TIF. **2020**,	
472	Image_2.TIF. **2020**,	
471	Table_1.DOCX. **2020**,	
470	Table_2.docx. **2020**,	
469	Table_3.docx. **2020**,	
468	Data_Sheet_1.docx. **2019**,	
467	Table_1.XLSX. **2019**,	
466	Table_2.XLSX. **2019**,	
465	Table_3.XLSX. **2019**,	
464	Table_4.XLSX. **2019**,	

463   Table_5.XLSX. **2019**,

462   Table_6.XLSX. **2019**,

461   Table_7.XLSX. **2019**,

460   Table_8.XLSX. **2019**,

459   Table_9.XLSX. **2019**,

458   Presentation_1.PDF. **2018**,

457   Presentation_2.PDF. **2018**,

456   DataSheet_1.zip. **2019**,

455   Data_Sheet_1.docx. **2020**,

454   Table_1.docx. **2020**,

453   Data_Sheet_1.XLSX. **2018**,

452   Data_Sheet_2.CSV. **2018**,

451   Data_Sheet_3.CSV. **2018**,

450   Image_1.JPEG. **2020**,

449   Image_2.JPEG. **2020**,

448   Image_3.JPEG. **2020**,

447   Image_4.JPEG. **2020**,

446   Image_5.JPEG. **2020**,

445   Image_6.JPEG. **2020**,

444   Table_1.docx. **2020**,

443   Image_1.TIFF. **2018**,

442   Table_1.XLSX. **2018**,

441   Data_Sheet_1.docx. **2020**,

440   Image_1.TIF. **2020**,

439   Image_2.TIF. **2020**,

438   Image_3.TIF. **2020**,

437   Image_4.TIF. **2020**,

436   Image_5.TIF. **2020**,

435   Image_6.TIF. **2020**,

434   Table_1.docx. **2020**,

433   Table_2.docx. **2020**,

432   Table_3.docx. **2020**,

431   Image_1.tif. **2020**,

430   Image_2.tif. **2020**,

429   Table_1.docx. **2020**,

428   Table_1.docx. **2019**,

427   Table_1.XLSX. **2020,**

426   Table_1.XLSX. **2020,**

425   Table_1.xlsx. **2019,**

424   Table_10.xlsx. **2019,**

423   Table_11.xlsx. **2019,**

422   Table_12.xlsx. **2019,**

421   Table_13.xlsx. **2019,**

420   Table_14.xlsx. **2019,**

419   Table_15.xlsx. **2019,**

418   Table_2.xlsx. **2019,**

417   Table_3.xlsx. **2019,**

416   Table_4.xlsx. **2019,**

415   Table_5.xlsx. **2019,**

414   Table_6.xlsx. **2019,**

413   Table_7.xlsx. **2019,**

412   Table_8.xlsx. **2019,**

411   Table_9.xlsx. **2019,**

410   Data_Sheet_1.pdf. **2020,**

409   Image_1.JPEG. **2018**,

408   Image_2.JPEG. **2018**,

407   Data_Sheet_1.docx. **2020**,

406   Table_2.XLSX. **2020**,

405   Table_4.DOCX. **2020**,

404   Image_1.tif. **2019**,

403   Table_1.xlsx. **2019**,

402   Table_2.xlsx. **2019**,

401   Table_1.docx. **2020**,

400   Image_1.TIF. **2020**,

399   Image_2.TIF. **2020**,

398   Image_3.TIF. **2020**,

397   Image_4.TIF. **2020**,

396   Image_1.tif. **2021**,

395   Image_2.tif. **2021**,

394   Image_3.tif. **2021**,

393   Image_4.tif. **2021**,

392   Image_5.tif. **2021**,

391   Image_6.tif. **2021**,

390   Table_1.xlsx. **2021**,

389   Data_Sheet_1.docx. **2019**,

388   Data_Sheet_2.xlsx. **2019**,

387   Presentation_1.pptx. **2020**,

386   Table_1.xlsx. **2020**,

385   Table_2.xlsx. **2020**,

384   Table_3.xlsx. **2020**,

383   Image_1.TIF. **2020**,

382   Image_2.TIF. **2020**,

381   Image_3.TIF. **2020**,

380   Image_1.JPEG. **2019**,

379   Image_2.JPEG. **2019**,

378   Image_3.JPEG. **2019**,

377   Image_4.JPEG. **2019**,

376   Image_5.JPEG. **2019**,

375   Image_6.JPEG. **2019**,

374   Table_1.XLSX. **2019**,

373   Table_2.XLSX. **2019**,

372   Data_Sheet_1.docx. **2020**,

371   Data_Sheet_2.docx. **2020**,

370   Image_1.jpg. **2020**,

369   Image_2.jpg. **2020**,

368   Image_3.jpg. **2020**,

367   Image_4.jpg. **2020**,

366   Image_5.jpg. **2020**,

365   Image_6.jpg. **2020**,

364   Image_7.jpg. **2020**,

363   Image_8.jpg. **2020**,

362   Image_9.jpg. **2020**,

361   Data_Sheet_1.docx. **2018**,

360   Image_1.TIFF. **2018**,

359   Image_2.TIFF. **2018**,

358   Table_1.DOCX. **2018**,

357   Image_1.PNG. **2020**,

356   Image_2.PNG. **2020**,

355   Image_3.PNG. **2020**,

354   Table_1.DOCX. **2020**,

353   Table_2.XLSX. **2020**,

352   Table_3.XLSX. **2020**,

351   DataSheet1.DOCX. **2018**,

350   MEOX2 homeobox gene promotes growth of malignant gliomas.. **2022**,   0

349   The miR-142 Suppresses U-87 Glioblastoma Cell Growth by Targeting EGFR Oncogenic Signaling
       Pathway.. **2021**, 20, 202-212

348   Gene Expression Subtyping Reveals Immune alterations:TCGA Database for Prognosis in Ovarian   2
       Serous Cystadenocarcinoma. **2021**, 8, 619027

347   EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a non-canonical regulatory
       axis between EGFR and wild-type p53 in glioblastoma.. **2022**,

346   Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.. **2022**, 15, 437-468   1

345   Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4
       Stem-like Cells.. **2022**, 23,

344   Artificial intelligence in cancer target identification and drug discovery.. **2022**, 7, 156   1

343   TNFRSF13B is a potential contributor to prostate cancer.. **2022**, 22, 180

342   Combined treatment with niclosamide and camptothecin enhances anticancer effect in U87 MG   1
       human glioblastoma cells.. **2022**, 13, 642-658

341   Epidemiology of Glioblastoma Multiforme⎯Literature Review. **2022**, 14, 2412   9

340   The translational challenges of precision oncology.. **2022**,   3

339   Advances in designing of polymeric micelles for biomedical application in brain related diseases..   4
       2022, 361, 109960

338   Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade   1
       glioma.. **2022**, 30, 100801

337	Whole exome sequencing reveals the genetic heterogeneity and evolutionary history of primary gliomas and matched recurrences. **2022**, 20, 2235-2246	0
336	Molecular Progression of Breast Cancer and Personalized Medicine in Terms of Clinical Trials. **2022**, 367-401	
335	Inference of Molecular Regulatory Systems Using Statistical Path-Consistency Algorithm. **2022**, 24, 693	
334	Gliomas: Genetic alterations, mechanisms of metastasis, recurrence, drug resistance, and recent trends in molecular therapeutic options.. **2022**, 115090	0
333	Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?. **2022**, 14, 2416	4
332	Improvements Achieved by Multiple Imputation for Single-Cell RNA-Seq Data in Clustering Analysis and Differential Expression Analysis.. **2022**,	0
331	Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas. **2022**, 14, 2454	0
330	Major Features of the 2021 WHO Classification of CNS Tumors.. **2022**,	2
329	MutaXome: A Novel Database for Identified Somatic Variations of Analyzed Cancer Exome Datasets.. **2022**, 21, 11769351221097593	2
328	Pericytes and Astrocytes Instruct Glioblastoma Invasion, Proliferation, and Therapeutic Response within an Engineered Brain Perivascular Niche Model.	0
327	Identification of an endoplasmic reticulum stress-related signature associated with clinical prognosis and immune therapy in glioma. **2022**, 22,	
326	Investigating the Interactions of Glioma Stem Cells in the Perivascular Niche at Single-Cell Resolution using a Microfluidic Tumor Microenvironment Model. 2201436	0
325	Intracranial Tumors. **2022**, 177-199	
324	Dialogue among Lymphocytes and Microglia in Glioblastoma Microenvironment. **2022**, 14, 2632	0
323	Updates in IDH-Wildtype Glioblastoma.	1
322	Exosomal circRNA BTG2 derived from RBP-J overexpressed-macrophages inhibits glioma progression via miR-25-3p/PTEN. **2022**, 13,	2
321	Identification of Potential Biomarkers for Pan-Cancer Diagnosis and Prognosis Through the Integration of Large-Scale Transcriptomic Data. 13,	1
320	Machine learning and bioinformatics approaches for classification and clinical detection of bevacizumab responsive glioblastoma subtypes based on miRNA expression. **2022**, 12,	

319	Role of CDH23 as a prognostic biomarker and its relationship with immune infiltration in acute myeloid leukemia. **2022**, 22,	0
318	A methylation-driven genes prognostic signature and the immune microenvironment in epithelial ovarian cancer.	
317	Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. **2022**,	0
316	Overlapping group screening for detection of gene-environment interactions with application to TCGA high-dimensional survival genomic data. **2022**, 23,	0
315	Radiation therapy promotes unsaturated fatty acids to maintain survival of glioblastoma.	0
314	Epigenetic Signatures of Centrosomes Are Novel Targets in Cancer Diagnosis: Insights from an Analysis of the Cancer Genome Atlas. **2022**, 6, 14	0
313	Pyroptosis-related prognosis model, immunocyte infiltration characterization, and competing endogenous RNA network of glioblastoma. **2022**, 22,	0
312	Towards Digital Twin Oriented Modelling of Complex Networked Systems and Their Dynamics: A Comprehensive Survey. **2022**, 1-1	2
311	Analyse de l'impact des résultats du séquençage de nouvelle génération chez les patients atteints de glioblastome. **2022**,	
310	PRLHR Immune Genes Associated With Tumor Mutation Burden can be Used as Prognostic Markers in Patients With Gliomas. 12,	
309	Somatic point mutations are enriched in non-coding RNAs with possible regulatory function in breast cancer. **2022**, 5,	0
308	S645C Point Mutation Suppresses Degradation of EGFR to Promote Progression of Glioblastoma. 12,	
307	A scalable, open-source implementation of a large-scale mechanistic model for single cell proliferation and death signaling. **2022**, 13,	0
306	Abrogation of Rb Tumor Suppression Initiates GBM in Differentiated Astrocytes by Driving a Progenitor Cell Program. 12,	
305	Screening of potential novel candidate genes in schwannomatosis patients.	1
304	Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma.	
303	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?.	1
302	The Current State of Glioma Data Registries.	

| 301 | Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome. | 3 |

| 300 | Iron commensalism of mesenchymal glioblastoma promotes ferroptosis susceptibility upon dopamine treatment. **2022**, 5, | 0 |

| 299 | Rapid Actions of the Nuclear Progesterone Receptor through cSrc in Cancer. **2022**, 11, 1964 | 0 |

| 298 | Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era. 13, | 0 |

| 297 | Analysis of the expression, function and signaling of glycogen phosphorylase isoforms in hepatocellular carcinoma. **2022**, 24, | |

| 296 | The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies. | 0 |

| 295 | Expression profile of radiotherapy sensitive genes and tumor-associated immune cell infiltration and prognosis in multiple human cancers. **2022**, 15, 5-11 | |

| 294 | Tumor‐Host Interactions in Malignant Gliomas. **2022**, 509-518 | |

| 293 | Genomic Landscape and Immunological Profile of Glioblastoma in East Asians. | |

| 292 | A novel defined risk signature of interferon response genes predicts the prognosis and correlates with immune infiltration in glioblastoma. **2022**, 19, 9481-9504 | |

| 291 | A Comprehensive Clinical Review of Adult-Type Diffuse Glioma Incorporating the 2021 World Health Organization Classification. **2022**, 12, 43-70 | |

| 290 | The role of shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells. **2022**, 102987 | 1 |

| 289 | The Progression Related Gene RAB42 Affects the Prognosis of Glioblastoma Patients. **2022**, 12, 767 | 1 |

| 288 | A Survey of Radiomics in Precision Diagnosis and Treatment of Adult Gliomas. **2022**, 11, 3802 | 1 |

| 287 | MicroRNA-219 loaded chitosan nanoparticles for treatment of glioblastoma. **2022**, 50, 198-207 | 0 |

| 286 | Differential migration mechanics and immune responses of glioblastoma subtypes. | |

| 285 | Hedgehog signaling regulates the development and treatment of glioblastoma (Review). **2022**, 24, | |

| 284 | Identification of BST2 Contributing to the Development of Glioblastoma Based on Bioinformatics Analysis. 13, | |

265   Capturing the latent space of an Autoencoder for multi-omics integration and cancer subtyping. **2022**, 148, 105832   0

264   Tumors of the nervous system. **2023**, 203-228

263   Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD+ Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase. **2022**, 14, 3572   0

262   Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases. 2201740   2

261   A Proteomic Platform Unveils the Brain Glycogen Phosphorylase as a Potential Therapeutic Target for Glioblastoma Multiforme. **2022**, 23, 8200

260   Multi-view Omics Translation with Multiplex Graph Neural Networks. **2022**,

259   PTEN Dual Lipid- and Protein-Phosphatase Function in Tumor Progression. **2022**, 14, 3666   0

258   A Quantitative Digital Analysis of Tissue Immune Components Reveals an Immunosuppressive and Anergic Immune Response with Relevant Prognostic Significance in Glioblastoma. **2022**, 10, 1753   0

257   The novel compensatory reciprocal interplay between neutrophils and monocytes drives cancer progression.

256   Looking Beyond the Glioblastoma Mask: Is Genomics the Right Path?. 12,   0

255   Basic premises: searching for new targets and strategies in diffuse gliomas.   0

254   Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas. **2022**, 81, 707-716

253   Molecular matched targeted therapies for primary brain tumors single center retrospective analysis.   1

252   SAFARI: shape analysis for AI-segmented images. **2022**, 22,   0

251   GPCR genes as a predictor of glioma severity and clinical outcome. **2022**, 50, 030006052211139   0

250   Anti-Migratory Effect of Dipotassium Glycyrrhizinate on Glioblastoma Cell Lines: Microarray Data for the Identification of Key MicroRNA Signatures. 12,

249   Probabilistic Edge Inference of Gene Networks with Bayesian Markov Random Field Modelling.

248   Modeling the role of HIF in the regulation of metabolic key genes LDH and PDH: Emergence of Warburg phenotype. **2022**, 2,

229	Brain Tumor Characterization Using Radiogenomics in Artificial Intelligence Framework. **2022**, 14, 4052	2
228	Neurotransmitters: Potential Targets in Glioblastoma. **2022**, 14, 3970	1
227	Design, synthesis, and biological evaluation of novel dual inhibitors of heat shock protein 90/mammalian target of rapamycin (Hsp90/mTOR) against bladder cancer cells. **2022**, 242, 114674	
226	Membrane-associated RING-CH protein (MARCH8) is a novel glycolysis repressor targeted by miR-32 in colorectal cancer. **2022**, 20,	0
225	Epigenetic Suppression of the IL-7 Pathway in Progressive Glioblastoma. **2022**, 10, 2174	0
224	Anticancer effects of OSW-1 on glioma cells via regulation of the PI3K/AKT signal pathway: A network pharmacology approach and experimental validation in vitro and in vivo. 13,	1
223	The role of mixed lineage kinase 3 (MLK3) in cancers. **2022**, 238, 108269	0
222	Integration of differential expression and network structure for Ξmics data analysis. **2022**, 150, 106133	0
221	The mitotic regulator RCC2 promotes glucose metabolism through BACH1-dependent transcriptional upregulation of hexokinase II in glioma. **2022**, 549, 215914	0
220	A nonlinear model and an algorithm for identifying cancer driver pathways. **2022**, 129, 109578	0
219	Discovery of druggable cancer-specific pathways with application in acute myeloid leukemia. **2022**, 11,	0
218	Horizontal Integration: Disease ΞCancer Systems Biology. **2022**,	0
217	Multi-agent Feature Selection for Integrative Multi-omics Analysis. **2022**,	0
216	Tangent normalization for somatic copy-number inference in cancer genome analysis.	0
215	Prediction of cancer driver genes through integrated analysis of differentially expressed genes at the individual level.	0
214	Co-amplified with PDGFRA , IGFBP7 is a prognostic biomarker correlated with the immune infiltrations of glioma.	0
213	Protein Quality Control in Glioblastoma: A Review of the Current Literature with New Perspectives on Therapeutic Targets. **2022**, 23, 9734	1
212	A comprehensive review of SHP2 and its role in cancer.	1

211	Transcriptomic Harmonization as the Way for Suppressing Cross-Platform Bias and Batch Effect. **2022**, 10, 2318	0
210	The Critical Role of RNA m6A Methylation in Gliomas: Targeting the Hallmarks of Cancer.	0
209	MEX3A impairs DNA mismatch repair signaling and mediates acquired temozolomide resistance in glioblastoma.	0
208	Sex differences in brain tumor glutamine metabolism reveal sex-specific vulnerabilities to treatment. **2022**,	0
207	Non-coding RNAs and glioma: Focus on cancer stem cells. **2022**,	0
206	Multi-modality artificial intelligence in digital pathology.	2
205	EGFR, the Lazarus target for precision oncology in glioblastoma.	1
204	HECTD3 regulates the tumourigenesis of glioblastoma by polyubiquitinating PARP1 and activating EGFR signalling pathway.	0
203	Diagnostic Value of Nestin Expression in Adult Gliomas. 106689692211257	0
202	The impact of heme biosynthesis regulation on glioma aggressiveness: Correlations with diagnostic molecular markers. 15,	0
201	Role of miRNAs in the regulation of cancer-associated signaling pathways. **2022**,	0
200	Molecular Genetic Profile of 300 Japanese Patients with Diffuse Gliomas Using a Glioma-tailored Gene Panel. **2022**, 62, 391-399	0
199	Novel Laser Capture Microdissection-Proteomic Analysis Identifies Spatially Distinct Extracellular Matrix Signatures in the Core and Infiltrating Edge of Human Glioblastoma.	0
198	A 9-gene prognostic signature for kidney renal clear cell carcinoma overall survival based on co-expression and regression analyses.	0
197	Integration of Gene Expression and DNA Methylation Data Across Different Experiments.	0
196	A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. **2022**, 185, 3807-3822.e12	6
195	Establishment and characteristics of GWH04, a new primary human glioblastoma cell line. **2022**, 61,	0
194	Interpretation of the role of germline and somatic non-coding mutations in cancer: expression and chromatin conformation informed analysis. **2022**, 14,	0

193	Current therapeutic options for glioblastoma and future perspectives. 1-12	1
192	Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges.	1
191	Injury programs shape glioblastoma. **2022**,	0
190	Prognostic Impact of Low-Level p53 Expression on Brain Astrocytomas Immunopositive for Epidermal Growth Factor Receptor. **2022**, 44, 4142-4151	0
189	Glioma stem cell signature predicts the prognosis and the response to tumor treating fields treatment.	2
188	Perivascular Stromal Cells Instruct Glioblastoma Invasion, Proliferation, and Therapeutic Response within an Engineered Brain Perivascular Niche Model. 2201888	0
187	Rewired Metabolism of Amino Acids and Its Roles in Glioma Pathology. **2022**, 12, 918	1
186	Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods.	0
185	Cell cultures in assessing radioresistance of glioblastomas. **2022**, 86, 126	0
184	Proteomics of Extracellular Vesicle in Glioblastoma. **2022**, 10, 207	0
183	Genetic Analysis Implicates Dysregulation of SHANK2 in Renal Cell Carcinoma Progression. **2022**, 19, 12471	0
182	Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla⃝EGFR Testing Platform. **2022**, 29, 7900-7911	0
181	The interferon-inducible protein viperin controls cancer metabolic reprogramming to enhance cancer progression.	0
180	CXCR4 expression is associated with proneural-to-mesenchymal transition in glioblastoma.	0
179	What Is a Digital Twin? Experimental Design for a Data-Centric Machine Learning Perspective in Health. **2022**, 23, 13149	0
178	Cancer Genomics and Evolution. 1-30	0
177	Transcriptomic and connectomic correlates of differential spatial patterning among gliomas.	0
176	Imaging of GBM in the Age of Molecular Markers and MRI Guided Adaptive Radiation Therapy. **2022**, 11, 5961	0

175	De novo analysis of bulk RNA-seq data at spatially resolved single-cell resolution. **2022**, 13,	1
174	A Vision for Twenty-First Century Healthcare. 1-8	0
173	Clinical and Research Informatics Data Strategy for Precision Oncology. 1-9	0
172	Targeting tumour-intrinsic neural vulnerabilities of glioblastoma.	0
171	A new machine learning method for cancer mutation analysis. **2022**, 18, e1010332	0
170	Systems Biology and Genomics. 1-11	0
169	Cancer Bioinformatics. 1-14	0
168	The miR-429 suppresses proliferation and migration in glioblastoma cells and induces cell-cycle arrest and apoptosis via modulating several target genes of ERBB signaling pathway.	0
167	Tau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma. **2022**, 14, 5386	0
166	Smart chlorotoxin-functionalized liposomes for sunitinib targeted delivery into glioblastoma cells. **2022**, 77, 103908	0
165	Effect of the m6ARNA gene on the prognosis of thyroid cancer, immune infiltration, and promising immunotherapy. 13,	0
164	TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment.	0
163	Multi-regional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos.	0
162	Targeting K-Ras-mediated DNA damage response in radiation oncology: Current status, challenges and future perspectives. **2023**, 38, 6-14	0
161	Benzene fused pyrimidine-based derivatives and their biological properties. **2023**, 165-191	0
160	Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. **2022**, 35, 803-813	2
159	The role of RNA modification in the generation of acquired drug resistance in glioma. 13,	0
158	Probabilistic edge inference of gene networks with markov random field-based bayesian learning. 13,	0

157	LTB4R Promotes the Occurrence and Progression of Clear Cell Renal Cell Carcinoma (ccRCC) by Regulating the AKT/mTOR Signaling Pathway. **2022**, 11, 3606	1
156	Quisinostat is a brain-penetrant radiosensitizer in glioblastoma.	0
155	Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts. **2022**, 12,	0
154	A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution. 12,	0
153	SyBLaRS: A web service for laying out, rendering and mining biological maps in SBGN, SBML and more. **2022**, 18, e1010635	0
152	Transcriptional Profiling Reveals Mesenchymal Subtypes of Small Cell Lung Cancer with Activation of the Epithelial-to-Mesenchymal Transition and Worse Clinical Outcomes. **2022**, 14, 5600	0
151	circSMARCA5 Is an Upstream Regulator of the Expression of miR-126-3p, miR-515-5p, and Their mRNA Targets, Insulin-like Growth Factor Binding Protein 2 (IGFBP2) and NRAS Proto-Oncogene, GTPase (NRAS) in Glioblastoma. **2022**, 23, 13676	0
150	Targeted DNA sequencing to identify genetic aberrations in glioblastoma that underlie venous thromboembolism; a cohort study. **2022**,	0
149	A combination of Metformin and Epigallocatechin Gallate Potentiates Glioma Chemotherapyin vivo.	0
148	MUC16 mutation is associated with tumor grade, clinical features, and prognosis in glioma patients. **2022**,	0
147	Superenhancer-activation of KLHDC8A drives glioma ciliation and hedgehog signaling.	0
146	Treatment of Adult Gliomas: A Current Update. **2022**, 15,	0
145	Classification and Diagnosis of Adult Glioma: A Scoping Review. **2022**, 15,	0
144	Nanoluciferase-based complementation assays to monitor activation, modulation and signaling of receptor tyrosine kinases (RTKs). **2022**,	0
143	Aberrant L-Fucose accumulation and increased core fucosylation are metabolic liabilities in mesenchymal glioblastoma.	1
142	Mutual regulation between phosphofructokinase 1 platelet isoform and VEGF promotes glioblastoma tumor growth. **2022**, 13,	0
141	Cell-free DNA-based liquid biopsies in neurology.	0
140	Neuronal and tumourigenic boundaries of glioblastoma plasticity. **2022**,	1

139	Rnd3 Is a Crucial Mediator of the Invasive Phenotype of Glioblastoma Cells Downstream of Receptor Tyrosine Kinase Signalling. **2022**, 11, 3716	0
138	A Novel Machine Learning Method for Mutational Analysis to Identifying Driver Genes in Breast Cancer.	0
137	Cost Matrix of Molecular Pathology in Glioma𝖳owards AI-Driven Rational Molecular Testing and Precision Care for the Future. **2022**, 10, 3029	0
136	Protection of the human gene research literature from contract cheating organizations known as research paper mills. **2022**, 50, 12058-12070	0
135	A Multimodal Atlas of Tumor Metabolism Reveals the Architecture of Gene-Metabolite Co-regulation.	0
134	Genomic profiling and network-level understanding uncover the potential genes and the pathways in hepatocellular carcinoma. 13,	0
133	PDPN contributes to constructing immunosuppressive microenvironment in IDH wildtype glioma.	1
132	Assessment and prediction of glioblastoma therapy response: challenges and opportunities.	1
131	Caspase-8 as a novel mediator linking Src kinase signaling to enhanced glioblastoma malignancy.	0
130	The Radiogenomic and Spatiogenomic Landscapes of Glioblastoma, and their Relationship to Oncogenic Drivers.	0
129	Molecular targeted therapy: A new avenue in glioblastoma treatment (Review). **2022**, 25,	0
128	Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications. **2022**, 1-15	0
127	Roadmap toward subtype-specific vulnerabilities in adult glioma. **2022**, 1,	0
126	Characterization of orthotopic xenograft tumor of glioma stem cells (GSCs) on MRI, PET and immunohistochemical staining. 12,	0
125	Reclassification of TCGA Diffuse Glioma Profiles Linked to Transcriptomic, Epigenetic, Genomic and Clinical Data, According to the 2021 WHO CNS Tumor Classification. **2023**, 24, 157	0
124	CACA guidelines for holistic integrative management of glioma. **2022**, 1,	0
123	Cell signaling activation and extracellular matrix remodeling underpin glioma tumor microenvironment heterogeneity and organization.	0
122	An integrated analysis of the cancer genome atlas data discovers a hierarchical association structure across thirty three cancer types. **2022**, 1, e0000151	0

121	FBXO42activity is required to prevent mitotic arrest, spindle assembly checkpoint activation, and lethality in glioblastoma and other cancers.	0
120	Glioblastoma cells have increased capacity to repair radiation-induced DNA damage after migration to the olfactory bulb. **2022**, 22,	0
119	BI-907828, a novel potent MDM2 inhibitor, inhibits GBM brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.	0
118	Lipid droplets and ferroptosis as new players in brain cancer glioblastoma progression and therapeutic resistance. 12,	0
117	The iron-modulating hormone hepcidin is upregulated and associated with poor survival outcomes in renal clear cell carcinoma. 13,	1
116	Intersections of Ubiquitin-Proteosome System and Autophagy in Promoting Growth of Glioblastoma Multiforme: Challenges and Opportunities. **2022**, 11, 4063	0
115	NAD+ biosynthesis as a collateral lethality target for precision oncology.	0
114	Identification, validation and biological characterization of novel Glioblastoma Tumour Microenvironment subtypes: Implications for precision immunotherapy. **2022**,	0
113	BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network.	0
112	Role of ZNF143 and Its Association with Gene Expression Patterns, Noncoding Mutations, and the Immune System in Human Breast Cancer. **2023**, 13, 27	0
111	A prognostic risk model for glioma patients by systematic evaluation of genomic variations. **2022**, 25, 105681	0
110	Deep DNA sequencing of MGMT, TP53 and AGT in Mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker.	0
109	Towards Image - Based Personalization of Glioblastoma Therapy A Clinical and Biological Validation Study of a Novel, Deep Learning - Driven Tumor Growth Model.	0
108	A DNA methylation atlas of normal human cell types. **2023**, 613, 355-364	2
107	Effect of the 3q26-coding oncogene SEC62 as a potential prognostic marker in patients with ovarian neoplasia. 13,	0
106	Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines. **2023**, 15, 531	0
105	Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation. **2023**, 24, 1727	1
104	Melanoma and GlioblastomaNot a Serendipitous Association. Publish Ahead of Print,	0

103	Monocyte-neutrophil entanglement in glioblastoma. **2023**, 133,	1
102	Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling. **2023**, 15, 460	0
101	Genetic evolution and cellular interactions within the tumour microenvironment determine glioblastoma progression. 12, 52	0
100	Highly Multiplexed Spatially Resolved Proteomic and Transcriptional Profiling of the Glioblastoma Microenvironment Using Archived Formalin-Fixed Paraffin-Embedded Specimens. **2023**, 36, 100034	0
99	Functional genomic analysis of adult and pediatric brain tumor isolates.	0
98	Association of RNA-modification ⌀writer⌀genes with prognosis and response to immunotherapy in patients with low-grade glioma. **2023**, 18, e0279119	0
97	Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. 12,	0
96	Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma. **2022**, 100946	0
95	Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery. **2023**, 15, 59	1
94	New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme. 866-888	0
93	The PTEN-associated immune prognostic signature reveals the landscape of the tumor microenvironment in glioblastoma. **2023**, 578034	0
92	Molecular pathology and clinical implications of diffuse glioma. Publish Ahead of Print,	0
91	The efficacy of targeted therapy combined with radiotherapy and temozolomide-based chemotherapy in the treatment of glioma: A systemic review and meta-analysis of phase II/III randomized controlled trials. 13,	0
90	A multidimensional atlas of human glioblastoma organoids reveals highly coordinated molecular networks and effective drugs.	0
89	Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors.	0
88	N-of-one differential gene expression without control samples using a deep generative model.	0
87	YAP nuclear translocation is regulated by EGFR activation through PTEN/AKT axis in glioblastomas. **2023**, 100053	0
86	Proteogenomics of diffuse gliomas reveal molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. **2023**, 14,	0

85	Transcriptomic analyses of patient peripheral blood with hemoglobin depletion reveal glioblastoma biomarkers. **2023**, 8,	0
84	Multimodal and Multiparametric Neuroimaging of Gliomas. **2023**, 3027-3054	0
83	Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022.	0
82	Tumour DNA Sequencing. **2023**, 81-99	0
81	TRIM8: a double-edged sword in glioblastoma with the power to heal or hurt. **2023**, 28,	0
80	The application of RNA sequencing in precision cancer medicine. **2023**,	0
79	Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line. **2023**, 24, 6998	0
78	Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma. **2023**, 14,	0
77	Live-attenuated Japanese encephalitis virus inhibits glioblastoma growth and elicits potent antitumor immunity. 14,	0
76	Identifying cancer driver genes using a two-stage random walk with restart on a gene interaction network. **2023**, 158, 106810	0
75	Constructing metabolism-protein interaction relationship to identify glioma prognosis using deep learning. **2023**, 158, 106875	0
74	A new IRES-mediated truncated Cx32 isoform inhibits global mRNA translation to suppress glioblastoma. **2023**, 161, 114513	0
73	Automatic generation of pathological benchmark dataset from hyperspectral images of double stained tissues. **2023**, 163, 109331	0
72	Standardizing analysis of intra-tumoral heterogeneity with computational pathology.	0
71	Applications of deep learning in single-cell analysis.	0
70	Combined treatments with AZD5363, AZD8542, curcumin or resveratrol induce death of human glioblastoma cells by suppressing the PI3K/AKT and SHH signaling pathways. **2023**, 33, 101430	0
69	Study of Strawberry Notch homolog 1 and 2 expression in human glioblastoma. **2023**, 161, 515-523	0
68	MUC17 mutations are associated with poor prognosis in both adult low-grade glioma and glioblastoma patients.	0

67   Expanding the Disease Network of Glioblastoma Multiforme via Topological Analysis. **2023**, 24, 3075   o

66   Pharmacological Inhibition of Membrane Signaling Mechanisms Reduces the Invasiveness of U87-MG and U251-MG Glioblastoma Cells In Vitro. **2023**, 15, 1027   o

65   Lessons learned from evolving frameworks in adult glioblastoma. **2023**, 131-140   o

64   Interactive gene identification for cancer subtyping based on multi-omics clustering. **2023**, 211, 61-67   o

63   Adjuvant Vaccination with Allogenic Dendritic Cells Significantly Prolongs Overall Survival in High-Grade Gliomas: Results of a Phase II Trial. **2023**, 15, 1239   o

62   Modeling glioblastoma complexity with organoids for personalized treatments. **2023**, 29, 282-296   o

61   Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma. **2023**, 42, 112127   o

60   Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. **2023**, 15, 664   o

59   Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies. **2023**, 15, 547   o

58   ATP8B1 : A prognostic prostate cancer biomarker identified via genetic analysis. **2023**, 83, 602-611   o

57   Sorting nexin 10 sustains PDGF receptor signaling in glioblastoma stem cells via endosomal protein sorting. **2023**, 8,   o

56   Brain network mapping and glioma pathophysiology. **2023**, 5,   o

55   TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma. **2023**, 11, e006121   o

54   The Superoncogene Myc at the Crossroad between Metabolism and Gene Expression in Glioblastoma Multiforme. **2023**, 24, 4217   o

53   The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. **2023**, 161, 593-604   o

52   Deep learning MRI signature to predict survival and treatment benefit from temozolomide in IDH-wildtype glioblastoma. **2023**, 77, 102399   o

51   Updating TCGA glioma classification through integration of molecular profiling data following the 2016 and 2021 WHO guidelines.   o

50   Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance.   o

49	Identification and validation of a novel prognostic signature based on mitochondria and oxidative stress related genes for glioblastoma. **2023**, 21,	0
48	Characteristics of vasculogenic mimicry and tumour to endothelial transdifferentiation in human glioblastoma: a systematic review. **2023**, 23,	0
47	Cross-platform normalization enables machine learning model training on microarray and RNA-seq data simultaneously. **2023**, 6,	0
46	PDGF gene expression and p53 alterations contribute to the biology of diffuse astrocytic gliomas. **2023**, 8,	0
45	Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies. 14,	0
44	CRISPR/Cas9 screen uncovers functional translation of cryptic lncRNA-encoded open reading frames in human cancer. **2023**, 133,	1
43	Systems Medicine for Precise Targeting of Glioblastoma.	0
42	Self-organized metabotyping of obese individuals identifies clusters responding differently to bariatric surgery. **2023**, 18, e0279335	0
41	Exploring Novel Therapeutic Opportunities for Glioblastoma Using Patient-Derived Cell Cultures. **2023**, 15, 1562	0
40	Soluble Guanylate Cyclase ⊡ Subunit Represses Human Glioblastoma Growth. **2023**, 15, 1567	0
39	Evolution of cancer genomics and its clinical implications. **2019**, 9, 173-178	0
38	The Role of Long Noncoding RNAs in Glioblastoma: What the Neurosurgeon Should Know. **2023**, Publish Ahead of Print,	0
37	Identification of Genetic Alterations in Rapid Progressive Glioblastoma by Use of Whole Exome Sequencing. **2023**, 13, 1017	0
36	Multiplex single-cell chemical genomics reveals the kinase dependence of the response to targeted therapy.	0
35	The dark side of mRNA translation and the translation machinery in glioblastoma. 11,	0
34	Evaluation of rs10811661 polymorphism in CDKN2A / B in colon and gastric cancer.	0
33	Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents. **2023**, 28, 2587	0
32	PD-1/LAG-3 Dysfunctionality Signatures in Human Cancers.	0

31   Molecular determinants of neurocognitive deficits in glioma: based on 2021 WHO classification.   0

30   Antineoplastic Nature of WWOX in Glioblastoma Is Mainly a Consequence of Reduced Cell Viability and Invasion. **2023**, 12, 465   0

29   IDriveGenes: Cancer Driver Genes Prediction Using Machine Learning. **2023**, 11, 28439-28453   0

28   The role of lactate metabolism-related LncRNAs in the prognosis, mutation, and tumor microenvironment of papillary thyroid cancer. 14,   0

27   A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo. 14,   0

26   Data-driven spatio-temporal modelling of glioblastoma. **2023**, 10,   0

25   Astrocytic neoplasms. **2013**, 705-728   0

24   Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. **2023**, 24, 6184   0

23   Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data. **2023**, 18,   0

22   Kinome-wide synthetic lethal screen identifies PANK4 as modulator of resistance in glioblastoma´.   0

21   Editorial: Reviews in cancer metabolism. 13,   0

20   Protein disulfide-isomerase A4 confers glioblastoma angiogenesis promotion capacity and resistance to anti-angiogenic therapy. **2023**, 42,   0

19   Untargeted Metabolomic Characterization of Glioblastoma Intra-Tumor Heterogeneity Using OrbiSIMS. **2023**, 95, 5994-6001   0

18   Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). **2023**, 15, 2116   0

17   Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies.   0

16   Allograft inflammatory factor 1 is a potential diagnostic, immunological, and prognostic biomarker in pan-cancer. **2023**, 15, 2582-2609   0

15   Predicting the Driver Variants and Mutations in Lung Cancer Genome using Transcriptional Regulation Network. **2023**,   0

14   The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma. **2023**, 15, 1134   0

13	Exploring the role of cerebrospinal fluid as analyte in neurologic disorders. **2023**, 9,	0
12	Patient-derived glioblastoma neurosphere cultures differentially express nicotinic acetylcholine receptors depending on ambient choline.	0
11	Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.	0
10	Proteomic analysis reveals microvesicles containing NAMPT as mediators of radioresistance in glioma. **2023**, 6, e202201680	0
9	Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures. 13,	0
8	Accelerating the understanding of cancer biology through the lens of genomics. **2023**, 186, 1755-1771	0
7	Biomarkers for chemotherapy and drug resistance in the mismatch repair pathway. **2023**, 544, 117338	0
6	Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. **2023**,	0
5	Personalised therapeutic approaches to glioblastoma: A systematic review. 10,	0
4	CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway. **2023**, 14,	0
3	Immunotherapy in glioblastoma treatment: Current state and future prospects. 14, 138-159	0
2	Low-coverage and cost-effective whole-genome sequencing assay for glioma risk stratification.	0
1	Drug discovery and repositioning for glioblastoma multiforme and low-grade astrocytic tumors. **2023**, 147-200	0